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ABSTRACT  
This chapter reviews data that examine the relationship between androgens and coronary 
artery disease (CAD) in men. Androgens can exert both beneficial and deleterious actions 
on a myriad of factors implicated in the pathogenic mechanisms of atherosclerosis and CAD. 
Androgen/androgen receptor (AR) can modulate arterial disease and vascular function via 
genomic (AR) or non-genomic mechanisms in animal models and in vitro experimental 
studies. The diversity and complexity of the actions of testosterone (and its metabolites E2 
and DHT) and DHEA on the vasculature reflect the multiple cellular targets in the vessel 
wall, differences between species, gender, concomitant disease and, most importantly, 
level/dosage of testosterone exposure. 
 At present, it is not possible to determine the net effect of androgens on CAD pathogenesis 
and clinical outcomes. While observational clinical studies showed a consistent association 
between low testosterone and CAD (risk factors, events and mortality), and some 
experimental studies may suggest positive effects of androgens on CAD risk factors, body 
composition and individual vascular mechanisms, it is hazardous to suggest that 
manipulation of the androgenic milieu will result in clinical benefits in a complex multifactorial 
condition such as CAD. This ongoing uncertainty also underlines recent concerns regarding 
the possibility of adverse cardiovascular side effects in androgen treatment of endocrine and 
non-endocrine conditions, hampering efforts to exploit the potential therapeutic benefits of 
testosterone for men in the treatment of osteoporosis, sarcopaenia, chronic debilitating 
disease and obesity-related hypoandrogenism in the ageing male population. Large-scale 
prospective randomised placebo-controlled trials of sufficient size and duration are urgently 
needed to assess not only the benefits in terms of meaningful clinical benefits and patient-
important outcomes but also to document the risks of serious adverse events in testosterone 
treatment. In the meantime, for patients with established pathological hypogonadism, there 
are no substantive data to suggest that physiological testosterone therapy is associated with 
increased cardiovascular risk and their management should not deviate from current 
recommended practice. For complete coverage of this and related topics, please visit 
www.endotext.org. 
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INTRODUCTION 
Coronary artery disease (CAD) is one of the leading causes of mortality in men and women, 
being 5th in the rank order of disabilities in 1990. CAD is predicted to become the leading 
global cause of disease burden by 2020 (1). Current trends confirm the above prediction. In 
a report from the American College of Cardiology in 2012, CAD was estimated to result in 
17.3 million deaths worldwide each year (2). According to an estimate by the World Health 
Organisation, there will be 20 million deaths due to CAD globally in 2015. The age-adjusted 
morbidity and mortality rates from CAD are 2.5- to 4.5-fold higher in men than in women, the 
sex-specific gap narrowing after the menopause (3). The lifetime risk of CAD at the age of 
50 years is 1 in 2 for men and 1 in 2.5 for women (4). This male preponderance is 
remarkably consistent across 52 countries with hugely divergent rates of CAD mortality and 
lifestyles (5). The universality of this disparity makes it likely that there is an intrinsic sexual 
dimorphism in susceptibility to CAD that may involve genetic, hormonal, lifestyle or ageing 
factors. Sex hormones can influence a multitude of factors implicated in the pathogenesis of 
atherosclerosis and coronary artery disease - the traditional view being that androgens are 
harmful and estrogens beneficial but the oestrogen hypothesis was seriously challenged in 
light of the results from the Women’s Health Initiative (6,7). Indeed, the sex-specific disparity 
in CAD may involve diverse mechanisms ranging from in utero sex hormone imprinting, 
gender-specific behaviour, distribution of visceral body fat to vascular and myocardial 
structural/functional adaptation to ageing, pressure overload and disease (8). As the 
therapeutic applications for androgen administration widen to ‘non-classical’ indications (9) 
including male contraception, physiological ageing, chronic debilitating conditions and 
hormone replacement in postmenopausal women (10), it becomes increasingly pertinent to 
consider whether natural or induced changes in levels of testosterone or 
dehydroepiandrosterone (DHEA) will impact on the risks of coronary artery disease in men 
and women. This question is one of the major safety issues for androgen therapy. This 
chapter synthesises data from PubMed publications on a variety of disciplines into a global 
assessment of the relationship between androgens and CAD in men. The role of androgens 
in CV diseases in women is dealt with in the Female Reproduction section. 
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Testosterone and 
Coronary artery 
Disease 
Observational Clinical 
Studies 
It is important to 
emphasize the limitations 
of observational studies on 
the associations between 
serum levels of 
endogenous androgens 
and CAD. The CAD 
endpoints are extremely 
variable (mortality, 
morbidity such as 
myocardial infarction and 
angina, angiography, 
ultrasound, arterial 
calcification, post-mortem 
findings and unspecified 
‘cardiac events’). Study 
groups are heterogeneous 
in terms of age, number of 
subjects and selection 
criteria. Most CAD patients 
will be on medications and 
have modified their 
lifestyle. In some studies, 
selection of poorly-
matched controls may 
have introduced biases. 
The time interval from 
myocardial infarction (MI) 
to blood sampling varied 
from 3 months to many 
years and was not always 
standardised for diurnal 
variation of hormone 
levels. Not all studies 
adjusted for confounding 
factors such as smoking, 
blood pressure, obesity, 
diabetes, and 
KEY POINTS 
Observational clinical studies have shown a consistent 
association between low endogenous testosterone and 
CAD (coronary artery disease), CV (cardiovascular) risk 
factors as well as CV mortality. 
Low DHEAS levels also appear to be associated with 
CAD in observational clinical studies but interventional 
studies with DHEA have failed to show any significant 
cardiovascular benefits. 
Although some experimental studies with TRT 
(testosterone replacement therapy) suggest beneficial 
effects of testosterone on CV risk factors, at present TRT 
cannot be recommended for the treatment of these 
conditions in the absence of pathological hypogonadism. 
Apparently beneficial effects of TRT in patients with 
symptomatic CAD reported in preliminary clinical studies 
are unclear. TRT is contraindicated in heart failure. 
Recently, retrospective observational studies have raised 
concerns regarding increased risk of CV adverse events 
with TRT in elderly men. Although many small prospective 
clinical trials have shown no significant increase in CV 
events, they are insufficiently powered to assess this risk. 
Physicians should therefore be highly vigilant about the 
possibility of harm from TRT, particularly with higher 
doses in older men with pre-existing CAD or CV risk 
factors. 
The risk of increased venous thromboembolism with TRT 
is extremely low and appears to be mainly in patients with 
underlying genetic or acquired hypercoagulable states. 
Physiological TRT for patients with established 
pathological hypogonadism should not deviate from 
current recommended practice as there are no 
substantive data suggestive of increased CV (or prostate) 
disease risks. 
The initiation or continuation of TRT in newly diagnosed or 
established patients with pathological hypogonadism who 
have developed a new cardiovascular event should delay 
or stop treatment for 3 to 6 months 
Large-scale prospective randomised placebo-controlled 
trials of testosterone treatment for non-pathological 
‘hypogonadism’ of sufficient size and duration are urgently 
required to assess not only the benefits (in terms of 
meaningful clinical benefits and patient-important 
outcomes) but also to document any risks of serious 
adverse events. 
At present, it is not possible to determine the net effect of 
androgens on CAD pathogenesis or clinical outcomes. 
The possible benefits versus potential risks and the 
current lack of definitive safety data should be carefully 
discussed with each individual patient before starting 
TRT. 
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dyslipidemia. Finally, chronic illnesses including CAD can lower serum levels of 
testosterone; such a potential bi-directional relationship makes interpretation and deduction 
of clinical implication difficult. 
Endogenous testosterone and CAD  
Cross-Sectional Studies 
Of the cross-sectional studies (11-48) investigating the relationships between circulating 
testosterone and CAD in men, 20 of 42 showed no association while the remainder found 
lower levels of testosterone in cases compared to controls (Table 1a). Many of the studies 
did not have sufficient statistical power due to the small number of subjects investigated. 
Three larger studies (19,27) found a negative relationship between testosterone and 
ischaemic heart disease or abdominal aortic calcification. In one Korean study (49) which 
investigated 291 men (mean age 52.8 +/- 9.3 years) who were non obese, non-diabetic, 
normotensive and with no history of previous CAD, bioavailable testosterone was inversely 
associated with the coronary calcium score. A few studies (24,48,50,51) have also found an 
inverse correlation between testosterone and severity of CAD. As with all cross-sectional 
studies, the directionality between cause and consequence and the significance of the 
observed negative relationship is unclear.  
Prospective Cohort or Case-Control Studies: Association between Testosterone and coronary 
artery disease / cardiovascular events 
Eleven of eighteen (27,52-60) non-cross sectional studies showed no significant relationship 
or predictive value between testosterone and clinical or biochemical indicators of CAD 
(Table 1b).  
In the six prospective cohort studies which followed, 1009 Californian men aged 40-79 over 
12 years (53), 2512 men aged 45-59 in South Wales (Caerphilly) for 5 years (56), 890 
Baltimore men aged 53.816 yr for up to 31 years (58), 2084 men aged 5612 yr from 
Framingham, Massachusetts for 10 yrs (59), 1568 men from Tromso, Norway aged 59.610 
yrs for 10 years (60) and 254 elderly men of Framingham cohort with mean age of 75.5 yrs 
for 10 years (61), there was no correlation between baseline testosterone levels and 
subsequent development of fatal or non-fatal CAD, stroke or heart failure after adjusting for 
relevant confounders. 
In the Rotterdam study, 282 Dutch men were followed for 6.5 years (27) and this showed 
that low testosterone was associated with progression of abdominal aortic atherosclerosis 
detected by radiological calcification. The Japanese study which followed 171 middle aged 
men found that low testosterone was significantly associated with cardiovascular events 
(62). The Health in Men Study (HIMS) of Western Australia (63,64) showed that eutinising 
hormone (LH) levels had positive relationship with cardiovascular events and 
dihydrotestosterone had inverse relationship for ischaemic strokes. The 5 yr follow up study 
of 2416 community dwelling Swedish men of MrOS cohort (65) also demonstrated a 
significant inverse association between endogenous testosterone and major cardiovascular 
events.   
In a recent study which followed 3650 men aged >65 years from the French Three-City 
cohort for 4 years, a J shaped association between plasma total testosterone and coronary 
artery disease risk was found (66). In another recent study which followed 1032 American 
community dwelling men with mean age of 76 years for 9 years, similar J or U shaped 
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association was found between serum dihydrotestosterone levels and incident coronary 
artery disease (67). 
In the 4 case-control studies, baseline testosterone levels in cases of CAD and matched 
controls, from the Multiple Risk Factors Interventional Trial (52), Honolulu Heart Programme 
(54), Baltimore Longitudinal Study of Ageing (55) and the Helsinki Heart Study (57), did not 
predict CAD events during observation periods of 6-8, 19-20, 9.5 and 5 years, respectively. 
Prospective Cohort or Case-Control Studies: Association between Testosterone and 
Cardiovascular/all-cause Mortality  
There have been a number of recent publications describing the association between serum 
testosterone levels and cardiovascular mortality in middle-aged and older men followed for 3 
to 18 years (59,60,68-71) (Table 1c). 
In the Caerphilly (68), MMAS (69), Tromso (60) and Framingham Heart Study (61) cohorts, 
there was no significant association between testosterone and cardiovascular mortality. 
Possible explanations for the lack of a relationship in these cohorts include small sample 
size of elderly men with co-morbidities (61), younger age of the men studied (59,68,69), a 
relatively small number of deaths (60,68,69) and higher testosterone levels with a mean of 
16.1 nmol/L in men in the lowest quartile of serum testosterone (59,68).  
A number of studies have demonstrated significant associations between testosterone levels 
and cardiovascular as well as all-cause mortality. In the Rancho-Bernardo cohort, after 
adjusting for health status, adiposity and other cardiovascular risk factors, men with 
testosterone levels in the lowest quartile (mean 7.1nmol/L) had a 40% increased risk of 
cardiovascular death when compared with men in the highest quartile (mean 15.1nmol/L) 
(70). The association remained significant after accounting for the possibility of reverse 
causality by excluding deaths that occurred within the first five years of follow-up. When all-
cause mortality in this cohort was analysed as a function of deciles of total testosterone, no 
additional survival benefit was evident for men with a testosterone level above 10nmol/L. In 
the EPIC-Norfolk prospective population study (71) men with testosterone levels of 
9.5nmol/L had an almost 50% increased risk of cardiovascular death, after adjusting for 
other risk factors, when compared to men with testosterone levels of 24.2nmol/L. Again the 
association remained evident after excluding deaths within the first two years of follow-up. 
The MrOS Swedish cohort with a mean follow up of 4.5 years showed that men with lowest 
quartile of testosterone and low estrogen had increased risk of all-cause mortality which 
almost doubled (72). The Study of Health in Pomerania (SHIP) which followed 1954 men for 
an average of 7.2 years found a significant inverse association between serum total 
testosterone and mortality from all causes including cardiovascular events (73). The 
NHANES III prospective cohort study found that low free testosterone and low bioavailable 
testosterone at baseline were independently associated with higher risks of cardiovascular 
and all-cause mortality during the first 9 year but not the subsequent 9 to 18 year follow-up 
period (74). A prospective study of 1687 Italian men with erectile dysfunction found that low 
testosterone was significantly associated with higher mortality from major adverse 
cardiovascular events. In a longitudinal study of 930 UK men who had coronary angiogram 
followed for 6.9 years, low total and bioavailable testosterone had significant negative impact 
on survival (75).The LURIC study which followed 2069 German men referred for coronary 
angiography for 7.7 years demonstrated that low testosterone and low vitamin D were 
significantly associated with all-cause mortality (76). The HIM Study (77), which followed 
3637 elderly men for 5.1years, showed that low free testosterone, higher SHBG and higher 
LH levels were associated with cardiovascular mortality. The European Male Ageing study 
(EMAS) which followed 2599 European men for 4.3 years showed significant inverse 
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association between low total testosterone and all-cause mortality and cardiovascular 
mortality (78). In the Turku cohort of 187 non-diabetic men followed for 10 years, there was a 
significant inverse association between total testosterone and mortality (79). In a Veterans 
study which followed men >40 years of age for 4.3 years, comparison between men with 
testosterone <8.7 nmol/L with those with testosterone >12 nmol/L demonstrated increased 
mortality in men with low testosterone levels (80). In a prospective cohort study of 581 UK 
men with type 2 diabetes followed for 5.8 years, the risk of mortality increased in patients 
with baseline total testosterone <10.4 nmol/L; the risk of cardiovascular mortality significantly 
increased in those with total testosterone <8.4 nmol/L (81). The studies in the cohort of 
patients with chronic kidney disease on haemodialysis (82-85) also demonstrated significant 
negative association between testosterone and increased risk of mortality.  
In the recent analysis of the Veterans study which followed 1032 men with mean age of 76 
years for 9 years, J or U-shaped association was found between serum dihydrotestosterone 
levels and mortality (67). Further analysis of the HIM study from Western Australia also 
demonstrated J or U shaped association between dihydrotestosterone and cardiovascular 
and all-cause mortality (64,86). 
Araujo et al conducted a systematic review and meta-analysis of 12 community-based 
studies. They concluded that there was a significantly increased risk of both cardiovascular 
and all-cause mortality in men with low baseline testosterone (87). Corona et al, in their 
meta-analysis, also found that low testosterone and high oestradiol independently predicted 
an increased risk of CAD and mortality (88). In general, these meta-analyses have 
limitations due to between-study heterogeneity.  
In summary, only a minority of studies have shown no association between 
testosterone and CVD mortality. The majority of studies have demonstrated that CAD 
and cardiovascular deaths are more common in men with low testosterone. Recently 
two studies have raised the possibility that high levels of endogenous androgens may 
also increase the risk of CAD and mortality (J or U shaped association). Although the 
cause and effect nature of the relationship remains to be determined, it is likely that 
low testosterone is a biomarker for poor cardiovascular health. 
 
Klinefelter Syndrome 
Klinefelter syndrome, characterized by small testes, azoospermia, gynaecomastia and a 
variable degree of hypogonadism with a 47,XXY karyotype has a prevalence of 1 in 500 to 
640 men (89). It is estimated that more than 50% of cases are not diagnosed making 
Klinefelter syndrome potentially the largest single unrecognized (and thus untreated) cause 
of androgen deficiency in young men (90). Other clinical manifestations also occur in many 
systems aside from infertility and androgen deficiency (91) with increased mortality due to a 
variety of causes (92,93) resulting in a reduced life expectancy of 2.1 years (92). An 
increased IHD risk has been documented both before and after the diagnosis of Klinefelter 
syndrome (94). However, while circulatory system mortality was increased by 30-40% 
(92,93), the excess mortality was due to deaths from pulmonary embolism and peripheral 
vascular disease and IHD mortality was actually reduced (HR 0.7 [0.50-0.90]) (92,93). The 
relative contributions of the chromosomal abnormality itself, direct cardiovascular effects of 
testosterone, indirect effects of androgen deficiency including adiposity and diabetes 
mellitus, and lifestyle factors, such as smoking, are not known. These studies are also 
unable to account for the role of testosterone replacement therapy. A recent study (95) 
which investigated the nature of cardiovascular abnormalities in Klinefelter syndrome, 
demonstrated numerous abnormalities including left ventricular diastolic dysfunction, 
impaired cardiopulmonary performance, chronotropic incompetence, and increased intima-
media thickness which were not reversed by testosterone replacement therapy. These 
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abnormalities which seem to be more common in Klinefelter’s syndrome may represent the 
underlying pathophysiology for cardiovascular mortality (95). 
Interventional Clinical Studies 
The potential consequence of decreasing endogenous or increasing circulating levels of 
testosterone on CAD is discussed under various clinical interventional scenarios. 
Endogenous Androgen Deprivation 
Castration 
A frequently cited but misquoted study (96) compared the life expectancy of institutionalised 
mentally retarded castrated with intact white males; castrated males lived an average of 13.6 
years longer than intact controls. However, the excess mortality in intact inmates was due to 
infections with no difference in cardiovascular disease mortality between the two groups. 
The authors correctly concluded that post-pubertal castration did not decrease the frequency 
of deaths due to cardiovascular disease.  
Cross Gender Hormone Therapy 
Cross-gender anti-androgen treatment in 816 male-to-female orchidectomised transexuals 
aged 18-86 years (97) by administration of ethinylestradiol 100µg/day and cyproterone 
acetate 100mg/day for 7734 patient-years was not associated with any significant difference 
in arterial cardiovascular mortality or morbidity compared to the general male population 
despite a 20-fold increase in venous thromboembolic complications. A long term follow up 
study of 966 male-to-female transsexuals on different high dose estrogen regimens and 
cyproterone acetate 100 mg / day, followed up for a median of 18.5 years, found a higher 
mortality rate due to CAD in the individuals aged between 40 and 64 years (98). Another 
study which followed 100 transsexuals for an average of 10 years also found increased CAD 
risk in male-to-female transsexuals (99). A case control study which compared 214 male-to-
female transsexuals to age and gender matched controls with an average follow up period of 
7.4 years found a higher prevalence of CAD in transwomen (100). In the above studies 
estrogen treatment was also associated with CAD risk. In a recent study, transdermal 
estrogen preparations as compared to oral estrogen preparations have been shown to 
reduce cardiovascular risk in male to female transsexuals (101).  
Androgen Deprivation Therapy in Prostate Cancer 
Androgen deprivation therapy (ADT) is the mainstay of treatment for metastatic prostate 
cancer and is increasingly used in locally advanced disease. The resultant profound 
hypoandrogenism is associated with an adverse cardio-metabolic profile characterized by 
accumulation of body fat (102), reduction in insulin sensitivity (103), increase in the 
incidence of diabetes (104) and worsening of the control of diabetes among diabetic men 
(105). More recently it has been appreciated that the risk of cardiovascular disease (106-
110) is also significantly increased, and this, in addition to diabetes, is the leading cause of 
non-cancer deaths in prostate cancer survivors. 
An observational study of 73,196 men aged 66 years and older followed for 10 years found 
that GnRH agonist use was associated with a 16% increase in the risk of coronary heart 
disease and sudden cardiac death; the incident diabetes risk was increased by 44% (106). 
The increase in risk was evident after only 4 months of ADT and remained elevated for the 
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duration of treatment. In a further study of 5077 men stratified according to co-morbidities, 
established coronary artery disease, and the presence of cardiovascular risk factors, the 
excess risk was confined to those men with a history of myocardial infarction or heart failure.  
After 5 years, these men had a 2-fold increase in all-cause mortality with no increase seen in 
men with either no co-morbidities or a single cardiovascular risk factor (111).  
A meta-analysis from six observational studies of ADT reporting either CAD or 
cardiovascular mortality as outcome, with a total of 129,802 patients on ADT and 165,605 
controls showed that the incidence of CAD events was 10% higher in ADT group. 
Cardiovascular mortality was also significantly higher in the ADT group (112). Another meta-
analysis which included 126,898 patients in four cohort studies and 10,760 patients in nine 
randomised control trials showed a significant increase in cardiovascular morbidity 
associated with acute myocardial infarction and nonfatal CV events (113).  
Androgen Excess from Anabolic Steroid Abuse  
It should be emphasised that pathological data from men abusing anabolic-androgenic 
steroids (AAS) in doses several orders of magnitude higher than those prescribed in clinical 
practice should not be extrapolated to the legitimate therapeutic use of approved 
testosterone preparations or indeed to androgen physiology.  
AAS abuse, previously only prevalent in athletes and body builders (114,115), is said to 
have increased significantly in recent years, especially amongst adolescents (116,117). 
Case reports of cardiovascular events in young male body builders abusing pharmacological 
doses of multiple anabolic agents include arrhythmia, hypertension, acute myocardial 
infarction, cardiomyopathy and stroke (118). Postmortem examinations in 2 young body 
builders using AAS who died of acute myocardial infarction did not reveal any lesions in the 
coronary arteries (119). It is not possible to draw firm scientific conclusions about the cardiac 
toxicity or atherogenicity of AAS from these sporadic case reports, when the baseline 
denominator information on prevalence and extent of exposure is shrouded in uncertainty 
and secrecy. Nevertheless, it has been conjectured that dose-dependent androgen– induced 
vasospasm, endothelial dysfunction, platelet aggregation, activation of the coagulation 
cascade, atherogenic lipid profiles (decreased HDL–cholesterol and increased LDL-
cholesterol), and direct myocardial injury leading to abnormal left ventricular function 
(including diastolic dysfunction), cardiac hypertrophy and electrical remodelling are relevant 
mechanisms precipitating sudden cardiac deaths in young power athletes and body builders 
(118,120). 
Exogenous Testosterone Treatment in Ageing Men 
Observational studies 
A retrospective cohort study of men in the Veterans Affairs system with low testosterone who 
had CAD diagnosed by coronary angiography reported that men who received testosterone 
therapy had increased risk of cardiovascular events compared to those who did not (121). A 
second retrospective study which collected data from a large healthcare database in 
California, following an initial testosterone therapy prescription (n=55,593) reported 
increased risk of nonfatal MI in the first 90 days following the initial prescription as compared 
to one year prior initial prescription (122). In the most recent multi-cohort retrospective study 
including commercially-insured and Medicare populations in the United States and general 
practitioner’s records from the United Kingdom (n= 544115), safety of various dosage forms 
of testosterone preparations were compared. It showed that men who were prescribed 
injectable preparation of testosterone had a higher risk of cardiovascular events as 
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compared to gel preparation (HR 1.26; 95% CI 1.18-1.35) (123). Careful analysis of these 
studies shows several flaws which limit the conclusions that can be drawn about the 
relationship between CAD and testosterone therapy in these populations.  
 
Another retrospective observational study which analyzed data from 1031 male veterans 
showed that testosterone therapy in middle-aged hypogonadal men reduced mortality 
compared to those who did not receive testosterone therapy (124). The most comprehensive 
long term retrospective audit evaluating the safety of testosterone therapy in 401 
hypogonadal men with a mean follow up of 5.41 years did not find an increased risk of major 
adverse cardiovascular events compared to population with similar co-morbidities not on 
testosterone therapy (125). In a recently published observational study which analysed data 
of population-based cohort of men >66 years of age receiving intramuscular testosterone 
from a Medicare claims database, testosterone therapy was not associated with an 
increased risk of myocardial infarction (126). 
 
In the most recent retrospective observational analysis of community based healthcare 
system in Wisconsin which included 7245 hypogonadal men with mean age of 54 years, 
cardiovascular event rate was 5.5 % in men who received testosterone therapy compared to 
6.7% in the untreated arm at 3 year follow up. After adjustment for the baseline differences 
between treated and untreated patients, the difference in the cardiovascular event rate was 
not statistically significant (127).  
Placebo controlled trials 
A trial of testosterone therapy was terminated early as a result of adverse cardiovascular 
events in the Testosterone in Older Men with Mobility Limitations (TOM) trial, designed to 
determine the effects of testosterone for 6 months on leg strength and physical function in 
older men (128). Of the 209 men (mean age 74 years) randomized, 23 in the testosterone 
group compared to 5 in the placebo group experienced a cardiovascular-related adverse 
event. These men had a high rate of pre-existing cardiovascular disease (53%) and 
cardiovascular risk factors (hypertension 85%, diabetes 24%, hyperlipidaemia 63%, obesity 
45%) at baseline and were treated with a high dose (100mg/day) of testosterone gel to 
achieve a serum testosterone of 17.4-34.7mmol/l (500-1000ng/dL). Men exposed to 
testosterone levels in the highest quartile were at greatest risk (hazard ratio of 2.4). The trial 
was not designed to assess cardiovascular risk and the authors urged caution in interpreting 
the results because of the small number of events and limitations with respect to 
ascertainment of the adverse events. Furthermore, a very similar trial in frail elderly (>65 yr) 
men (129) using a more conventional dose (50mg/day) of testosterone gel daily showed no 
increase in CV events in the testosterone treated group during and after treatment.  
Meta-analyses 
Xu et al conducted a systematic review and meta-analysis of placebo-controlled randomized 
trials of testosterone therapy among men lasting 12+ weeks reporting CV-related events 
through the end of 2012. The 27 trials included 2,994 mainly older men with low testosterone 
and/or chronic diseases, who experienced 180 CV-related events; 33 CV-related deaths 
were identified. They concluded that CV related events varied with the source of funding 
showing increased risk in the trials not funded by pharmaceutical industry. However, the 
TOM trial which was the only one of the 27 studies to report a statistically significant 
increase in the CV events had a major and disproportionate impact on the analysis. In 
addition to this, there were several methodological limitations to this study which influenced 
the results of the meta-analysis (130).  
 
A meta-analysis of 19 randomized clinical trials conducted by Calof et al to determine the 
risks of adverse events associated with TRT (testosterone replacement therapy) in men ≥ 45 
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years of age with low or low-normal testosterone levels, found no significant differences in 
the rates of atrial fibrillation/arrhythmia, MI, chest pain/ischemia, coronary procedures or 
vascular events/cerebrovascular accidents between the testosterone and the placebo/non-
intervention groups (131). 
 
Haddad et al (132) conducted a systematic review and meta-analysis of 30 placebo 
controlled randomized trials which included 808 men in the testosterone replacement group 
and 834 men in the placebo group. It assessed the effect of testosterone use on CV events 
in men with different degrees of androgen deficiency. No significant differences were found 
among men receiving TRT compared with the control groups. Testosterone use in men with 
low testosterone levels led to changes in blood pressure and in all lipid fractions (total 
cholesterol, HDL cholesterol, LDL cholesterol, triglycerides). Results were similar in patients 
with low-normal to normal testosterone levels (132). 
 
Another meta-analysis conducted by Fernández-Balsells et al, was unable to discern any 
effect of testosterone on rates of death, myocardial infarction, revascularization procedures 
or cardiac arrhythmias in men with low/low-normal testosterone levels treated with 
testosterone for at least 3 months (133). However such risk estimates are imprecise 
because of the small numbers of subjects, short duration of treatment and limited number of 
events. None of the included studies were powered for actual cardiovascular events; 
additionally, several of the studies included men with significant co-morbidities (133). 
 
Ruige et al (2013) conducted a meta-analysis of 10 RCTs to evaluate the effect of 
testosterone treatment on CV risk. No statistically significant difference between placebo and 
testosterone treatment was found for testosterone treatment and CV-risk (134). 
 
Corona et al (2014) conducted a systematic review and meta-analysis on 75 placebo-
controlled randomised clinical trials with 3016 patients in the testosterone supplementation 
groups and 2448 patients in the untreated group. Mean duration of the treatment was 34 
weeks. This meta-analysis did not show a significant association between testosterone 
supplementation and major adverse CV events (135).  
 
In the most recent meta-analysis involving 29 heterogenous studies with 122,899 men, it 
was shown that testosterone therapy did not increase the risk of cardiovascular events 
significantly (RR 1.168, CI 0.794 – 1.718; P 0.431) (136).  
 
In summary, three retrospective studies (121-123), one placebo controlled trial, the 
TOM trial (128), and one meta-analysis which was largely based on the TOM trial, have 
reported increased risk of cardiovascular events with testosterone therapy. The men 
in these studies were older and had significant co-morbidities including CAD and CV 
risk factors. Reassuringly, a large number of studies, including several meta-
analyses, have shown no significant increase in the risk of cardiovascular events with 
testosterone therapy. Nevertheless, the unexpected finding of the TOM trial (128) and 
the reports of Vigen (121), Finkle (122) and Layton (123) should alert physicians and 
clinical investigators to the possibility of harm from testosterone treatment, 
particularly with higher doses, in older (>65 yr) men with pre-existing cardiovascular 
disease and/or risks factors.  
 
The US Food and Drug Authority (FDA) has recently instigated product labeling changes to 
include warnings regarding the potential increased risk of cardiovascular events with 
testosterone replacement therapy and strongly recommended further studies to investigate 
this possible association, while recognising that current evidence was inconclusive (137).  
 
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines 
Agency (EMA) concluded that there is no consistent evidence to support an increased risk of 
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heart problems associated with testosterone therapy in hypogonadal men. Nevertheless, 
PRAC recommended that product information of all testosterone-containing medicines in the 
European Union should be updated to include warnings against the use of these products in 
men suffering from severe heart, liver or kidney problems (138).  
Exogenous Testosterone Treatment in Men with CAD and Heart Failure  
Uncontrolled studies from the 1940s, largely of historical interests only, suggested that 
testosterone may improve symptomatic CAD in men. More recent data are considered 
below. 
Bolus intravenous or intracoronary injections of pharmacological doses of testosterone 
acutely improved myocardial ischaemia or induced coronary artery dilatation in a small 
number of men with CAD (139-141). Whether this acute pharmacological action of 
testosterone can be translated into a therapeutic effect remains to be determined.  
In a randomised placebo-controlled double-blind study, testosterone cypionate 200mg i.m. 
weekly for 8 weeks decreased ST segment depression during exercise testing in 25 men 
with positive tests (142). In a placebo-controlled crossover (but not double-blinded) study in 
62 elderly men with CAD, oral testosterone undecanoate for 4 weeks improved subjective 
symptom scores and resting ECG (143). Transdermal testosterone patch 5mg daily for 12 
weeks increased the time to 1-mm ST segment depression in men with symptomatic CAD 
(144) and oral testosterone selectively improved myocardial perfusion to areas supplied by 
unobstructed coronary arteries in men with coronary heart disease and baseline 
testosterone levels of 9nmol/L (145). 
These preliminary data suggest ECG changes can improve after (maximum of 12 weeks) 
short-term testosterone supplement in CAD patients with low testosterone levels. A small 
study of 13 men with testosterone levels <12nmol/L and angina found that the benefits of 
intramuscular testosterone on myocardial ischaemia (as determined by ST segment 
depression) were maintained at 12-months (146). In a double blind randomized placebo 
controlled trial 87 diabetic male subjects (mean age: 74+/-7 years) with proven CAD were 
randomized to a 12 week treatment with either testosterone undecanoate or placebo, 
testosterone therapy significantly reduced the number of anginal attacks/weeks of 34% 
(p<0.05); the silent ischemic episodes of 26% (p<0.05), and the total ischemic burden of 
21% (p<0.05) on ambulatory ECG monitoring (147).  
It is unclear whether the apparently beneficial effects of testosterone in CAD are due 
to direct coronary artery dilatation or due to its effects on skeletal muscle resulting in 
non-specific improvements in exercise performance or due to its effects on the brain, 
modulating the central pain pathway. It is also unclear whether testosterone therapy 
can provide real symptomatic and functional benefits in men with CAD.   
Currently, heart failure is a labeled contra-indication for testosterone treatment. However, 
there are recent limited data exploring the use of testosterone in patients with cardiac failure 
who frequently have low circulating testosterone levels. Cardiac output was acutely 
increased after two doses of buccal testosterone in men with heart failure (148), and 12 
weeks of intramuscular therapy improved peak oxygen consumption in elderly men with 
stable chronic heart failure (149). Over 12-months of follow-up, transdermal testosterone 
improved functional capacity in men with moderately severe heart failure when compared to 
placebo (150). In a double blind randomized controlled feasibility study of testosterone 
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therapy during exercise rehabilitation in male patients with chronic heart failure who had low 
testosterone, testosterone therapy improved indices like shuttle walk test, hand grip strength, 
leg strength, echocardiographic measures and body mass (151).  
Toma et al conducted a meta-analysis of 4 randomised controlled trials which showed that 
testosterone therapy was associated with a significant improvement in exercise capacity 
compared with placebo. The mean increase in the 6-minute walk test, incremental shuttle 
walk test, and peak oxygen consumption between the testosterone and placebo groups was 
54.0 m (95% CI, 43.0–65.0 m), 46.7 m (95% CI, 12.6–80.9 m), and 2.70 mL/kg per min (95% 
CI, 2.68–2.72 mL/kg per min), respectively. Testosterone therapy was associated with a 
significant increase in exercise capacity as measured by units of pooled SDs (net effect, 
0.52 SD; 95% CI, 0.10–0.94 SD). They did not find any significant adverse cardiovascular 
events (152). 
These preliminary findings require validation in rigorously controlled clinical trials and do not 
alter the current established indications and contra-indications for testosterone therapy, 
especially in light of recent concerns regarding CV safety (vide supra). 
In summary, the continuing uncertainty regarding CV adverse effects of testosterone 
treatment requires urgent investigation. Large-scale prospective randomised placebo-
controlled trials of sufficient size and duration are urgently needed to assess not only 
the benefits in terms of meaningful clinical benefits and patient-important outcomes 
but also to document the risks of serious adverse events in testosterone treatment. In 
the meantime, physicians should be mindful of the possibility of potential (serious) 
harm from testosterone treatment particularly in older men with pre-existing CV 
disease or risk factors. The balance of potential risk versus possible benefits and the 
current lack of definitive safety data should be carefully discussed with each 
individual patient before starting treatment. 
Dehydroepiandrosterone (DHEA) and Coronay artery disease (CAD) 
DHEA and its sulphate, DHEAS, are weak but highly abundant adrenal androgens which 
show a progressive age-related decline from the third decade onwards (153,154) . There is a 
body of opinion suggesting that DHEA supplementation may be beneficial to the elderly in a 
variety of physiological functions including the prevention of cardiovascular disease 
(155,156). It has been implied that, against an androgenic milieu in men, DHEA acts as a 
pro-hormone for conversion to metabolites with predominantly oestrogenic effects and 
potentially anti-atherogenic actions (157,158).  
Observational Clinical Studies  
DHEA and CAD 
Many observational studies in men have attempted to demonstrate a correlation between 
serum DHEAS levels and different CAD endpoints including the extent of atherosclerosis 
assessed by autopsy, coronary angiography, carotid vessel thickness/pulse wave, aortic 
calcification and clinical disease states including angina, myocardial infarction and mortality 
(Table 2). These have shown inverse (36,39,41,159-164) (mostly cross-sectional), null 
(24,27,39,43,161,164-170) or positive (30,57) relationships between DHEAS levels and CAD 
(Table 2). 
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Of the nested case control or prospective cohort studies, 10 of 21 studies (57,159,161,163) 
showed association between DHEAS levels and cardiac events (Table 2). In the Helsinki 
Heart Study of middle-aged dyslipidaemic men, higher DHEAS levels were associated with 
an increased risk of CAD (57). In the Honolulu Heart Study of 6000 men of Japanese 
descent followed for 18 years (161), low DHEA was associated with fatal but not non-fatal 
CAD. In the Rancho Bernardo cohort study, a preliminary report of 242 men also showed a 
negative relationship between DHEAS and CAD mortality (159). However, in the full analysis 
of the same study on 942 men over 19 years (164), there was only a modest negative 
relationship between DHEAS and those that survived their cardiac events, but none with 
CAD mortality. In the Swedish MrOS cohort, low DHEA and DHEAS were inversely 
associated with cardiovascular and all-cause mortality (171). Further analysis of the same 
cohort showed that low DHEA and DHEAS predict an increased risk of CAD (172). In the 
Vietnam Experience study involving 4255 US Vietnam – era army veterans followed up for 
15 years, DHEAS was inversely associated with cardiovascular and all-cause mortality 
(173). In the Cardiovascular Health Study - All Stars study, which followed 989 elderly men 
and women for 9 years, DHEAS was negatively associated with CAD (174). In the MMAS 
prospective cohort study which followed 1709 men aged 40 – 70 years for 9 years, low 
baseline DHEA and DHEAS predicted incident CAD (175). In the Rotterdam study which had 
1180 participants who were followed up for a mean of 12.3 years, low baseline DHEAS was 
shown to be an important indicator of future development of atrial fibrillation (176). In a study 
with 963 men and 1161 women of age 65-76 years and followed up for 7.4 years, there was 
no association of serum DHEAS with age adjusted all cause and CVD-mortalities (167). In 
the Framingham Heart Study which followed 1928 men for 10 years, the association of 
DHEAS with incident cardiovascular disease was not statistically significant (59). 
 
In summary, one cross-sectional study and one nested prospective case-control 
study of a small number of men, have shown positive associations of DHEAS with 
CAD and CV mortality. Few cross-sectional studies (24,27,38,43) and several 
prospective studies (55,59,161,164-170) including two large population-based studies 
(59,167) have not shown any association of DHEAS with CAD or CV mortality. A 
majority of the cross-sectional studies (36,39,41,160,162,163), and of prospective 
studies which included large number of men (164,171-176), have shown a negative 
association of DHEAS with CAD and CV mortality. Overall, it appears that DHEAS is 
negatively associated with CAD. DHEAS levels also appear to be associated with 
increased mortality from all causes of death in men over the age of 50 (161,164,166), 
giving rise to the notion that this is a non-specific marker of poor health and lack of 
adaptive capacity to acute illnesses or a secondary phenomenon consequent upon 
various diseases of ageing such as malignancies and heart failure (153,169,177). 
 
Interventional Studies with DHEAS  
In a mixed population of Addison’s disease and secondary hypoadrenalism (n=40), DHEA 
supplementation for 12 weeks normalized DHEAS and androstenedione (178). Apart from 
minor reductions of LDL-cholesterol, there were no other metabolic or vascular changes 
seen at the end of the study period (178). Administration of DHEA (25 mg od for 4 weeks) to 
12 eugonadal, hypercholesterolaemic men (mean age 54 years) improved brachial artery 
flow-mediated dilation (bFMD) and serum PAI-1 concentration when compared to a matched 
group treated with placebo (179). The only RCT which has investigated the effects of 50 mg 
of DHEA administration over 1 year in both men and women (n=280, age range: 60-79 
years) found that there were no significant benefits in men. Women above the age of 70 
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years, benefitted by increased bone density but aortic pulse wave velocity (aPWV) remained 
unchanged in either gender (180).  
Taken together, data from observational and interventional studies in men do not 
support the hypothesis that DHEAS ‘deficiency’ is a risk factor for CAD fatalities or 
that DHEA may confer an anti-atherogenic action in men. The interventional studies 
showed there were no discernible effects on vascular function in either short or long 
term in either gender. DHEA may be a non-specific marker for ill health in general.  
 
Androgens and arterial disease - Animal studies 
Androgen/androgen receptor (AR) can modulate arterial disease and vascular function (vide 
infra) via genomic (AR) or non-genomic mechanisms. The diversity and complexity of the 
actions of testosterone (and its metabolites E2 and DHT) on the vasculature reflect the 
multiple cellular targets in the vessel wall, differences between species, gender, concomitant 
disease and, most importantly, level/dosage of testosterone exposure. 
Animal Models 
The correlation between low circulating testosterone and atherosclerosis is one of the most 
important pieces of clinical evidence suggesting a potential cardiovascular benefit of 
androgen replacement therapy (ART) to hypogonadal men (181-183). However, the 
outcomes of recent clinical studies of androgen replacement therapy are controversial and 
contradictory, demonstrating an excess, null effect or reduction of cardiovascular events in 
apparently hypogonadal men using ART (121,122,128). Srininvas Shankar et al (184) and 
Shores et al (124) also showed no effect or apparent beneficial effect of testosterone 
replacement in hypogonadal or elderly men, respectively. In preclinical research, a number 
of animal models (predominantly in pigs, rabbits, rats or mice) have been developed to 
investigate different aspects of vascular pathology. Exploiting the power of these models to 
address the key mechanisms underpinning androgens and cardiovascular health is critical 
for interpretation of the complicated and inconsistent data generated from clinical and 
epidemiological studies. The models available can be broadly separated into investigations 
of atherosclerosis (using genetically-altered animals with or without modified diets) and of 
neointimal proliferation of the vascular wall (the fibroproliferative response to acute vascular 
injury). 
Models of Neointimal Lesion Formation 
Clinically, the acute formation of a fibroproliferative neointima in the blood vessel is most 
commonly seen after percutaneous vascular interventions (e.g. balloon angioplasty, 
stenting). It is attributed to the dramatic acute injury (stretching, removal of the endothelium) 
to the vessel wall, which produces an acute inflammatory and fibro-proliferative response 
characterized by infiltration and proliferation of smooth muscle-like cells in the sub-
endothelial space (185-188). Uncontrolled neointimal thickening, with narrowing of the 
lumen, may restrict blood flow and thus induce ischemia in the downstream tissue. Animal 
models of neointimal proliferation exploit this acute response by using a number of different 
techniques to induce lesion formation. These can be divided into techniques that remove the 
endothelium and those that do not. 
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Induction of Neointimal Lesions using Intraluminal Injury 
Neointima formation is induced by inserting an injuring device (e.g. balloon, wire, stent 
(185,186)) into a suitable artery to denude the endothelium and over-expand the medial 
layer. In mice, there is evidence that the neointimal lesion is formed predominantly from 
circulating bone marrow-derived progenitor cells (188). This is a good model in which to 
observe the vascular response to acute injury and study the mechanism of vascular 
inflammation and neointimal cell proliferation in the absence of conventional cardiovascular 
risk factors. 
Induction of Neointimal Lesions using Non-denuding Injury  
External, non-denuding injury can be induced by ligating the target artery or by placing a 
silastic cuff around the vessel. The mechanisms underlying lesion formation are not wholly 
clear but may involve disturbed blood flow and altered shear stress leading to endothelial 
dysfunction. Neointimal lesion formation occurs mainly through migration and proliferation of 
media-derived mural smooth muscle cells (187). In general, ligation injury causes less direct 
vascular damage than wire injury, producing smaller neointimal lesions. 
Models of Atherosclerosis 
Atherosclerosis can be induced using a “western-type” diet (high fat and/or high cholesterol 
diet) in experimental animals. The rabbit is a popular species in which to study 
atherosclerosis due to its high sensitivity to dietary cholesterol (189,190). With the 
establishment of transgenic mouse lines (e.g. apolipoprotein E deficient (apoE-/)- and low 
density lipoprotein receptor knockout (LDLR-/-), rodent models of diet-induced 
atherosclerosis are now widely used (190). Atherosclerotic lesions present a more complex 
pathology than injury-induced neointimal lesions, including leucocyte infiltration, foam cell 
formation, lipid deposition, vascular wall calcification and plaque erosion. As a consequence, 
characterization and quantification of atherosclerotic lesions may vary considerably 
depending on the artery selected for analysis and the technique (e.g. en face staining, 
histology, lipid extraction) used. This can complicate comparison between different 
investigations.  
Animal Models for Androgen Deficiency  
Orchidectomy (Odx) is used to abrogate endogenous testosterone production as a model to 
study the impact of hypogonadism. In recent years, transgenic mouse models have allowed 
us to manipulate the androgen receptor (AR) at global and cell-specific levels (191-193). 
Testicular feminized mice (Tfm), which have a non-functional AR (192), and global AR 
knockout mice (ARKO) (193), are both models of complete androgen insensitivity. These 
mice have cryptorchid testes and produce little testosterone. The circulating testosterone 
level in these mice is less than 10% of that in wild type mice (192,193). Testosterone 
replacement is often applied to these animals to investigate testosterone -mediated AR-
independent effects (193). 
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Androgen and Vascular Disease 
Androgen and Atherosclerosis 
The influence of androgens on the development of atherosclerosis has been investigated in 
a number of animal models (Table 3) (189,194-201). Driven by the clinical question of 
whether pharmacological androgen treatment is protective against atherosclerosis, the 
“castration plus androgen replacement therapy” model is widely used in preclinical studies. 
Androgens, including testosterone, dihydrotestosterone (DHT) and dehydroepiandrosterone 
(DHEA), have been consistently reported to suppress atherosclerosis in male animals in the 
past decades (195,199-201). This association is robust, when considering the wide range of 
techniques employed to quantify the atheroma, which include measuring: cholesterol content 
in homogenized arteries, plaque size based on histology, and lipid accumulation using en 
face oil-red staining. Evidence suggests that exogenous testosterone exerts a dose-
dependent inhibition on plaque development, even when extended to supra-physiological 
concentrations. Noticeably, the anti-atherosclerotic effect of androgens was only observed in 
males (194,196). Pharmacological testosterone for males has been demonstrated to 
exacerbate atherosclerosis in castrated females in multiple species including: monkeys, 
rabbits and mice (194,196,197). Given these observations, the following discussion will 
focus on the role of androgen in male cardiovascular health.  
Pharmacological tools have been widely employed to investigate whether the anti-
atherosclerotic effect of testosterone is mediated by AR-dependent signalling or by 
aromatase-dependent conversion of testosterone into estradiol. Li et al. reported that the AR 
antagonist flutamide reversed testosterone-mediated inhibition of atherosclerotic plaque 
formation in castrated rabbits, suggesting AR activation is required for inhibition of 
atherosclerosis (199). Nathan et al. showed that the aromatase inhibitor anastrazole 
counteracted the anti-atherosclerotic effect of testosterone in mice, demonstrating that 
testosterone-derived oestrogen also contributes to inhibition of atherosclerosis (198). 
Studies using transgenic mice with global AR insensitivity confirmed that AR activation is 
necessary for the protective effect of testosterone against atherosclerosis, but the finding 
that testosterone supplementation in AR deficient mice still reduced atherosclerotic plaque 
supports the existence of AR-independent mechanisms also (192,193). 
In contrast to atherosclerosis, neointimal lesion formation induced by acute mechanical 
injury, in the absence of cardiovascular risk factors, is mainly driven by infiltration and 
proliferation of smooth muscle-like cells (202). The evidence for androgens altering 
neointimal hyperplasia is limited and controversial. An inverse relationship between serum 
testosterone and neointima formation following angioplasty was reported in a male swine 
model. However, the inhibitory effect of testosterone was only observed in moderate injury 
but not in severe injury (203). Conversely, in a rat model, neither Odx nor Odx plus 
testosterone replacement altered neointima formation (204). More recently, we have 
demonstrated that endogenous but not exogenous testosterone reduced total neointimal 
volume (measured in 3-dimensions using optical projection tomography) but not maximum 
cross-sectional area (by conventional histology) (191). These data suggest that endogenous 
testosterone only exerts moderate suppression of neointimal cell recruitment/proliferation 
and could be overwhelmed by severe vascular injury. Further investigation using vascular 
smooth muscle and endothelial cell-specific AR knockout mice revealed that testosterone -
mediated inhibition of neointimal lesion formation is not dependent on vascular AR 
expression, which suggests that non-classical mechanisms (eg AR in non-vascular cells or 
AR-independent inhibition of lesion development) are involved in modulation of neotinimal 
proliferation. 
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Cell-specific Effects of Androgen  
It is difficult to determine the mechanism of androgen-mediated alteration in vascular 
remodeling using in vivo models. In vitro studies have shown that nitric oxide (NO) 
production is increased in endothelial cells upon stimulation with testosterone (205,206). NO 
is well known for its ability to suppress leukocyte adhesion and inhibit smooth muscle 
proliferation (207). Thus testosterone may promote vascular health via activation of 
endothelial NO production. Conversely, testosterone is reported to stimulate proliferation and 
migration in cultured smooth muscle cells (205,208), which is not consistent with its in vivo 
benefit in reducing vascular restenosis. Questions remain as to whether these counteracting 
mechanisms occur in vivo and what effect they have on regulation of vascular homeostasis. 
The mouse femoral artery ligation model preserves an intact endothelium and induces a mild 
injury, and is thus a useful tool to study the subtle balance between endothelial cells and 
smooth muscle cells. Using this model, endothelium selective AR deletion caused an 
increase in neointimal lesion formation, suggesting a protective role for endothelial AR. This 
effect was not observed, however, in mice with deletion of AR from both endothelium and 
smooth muscle, suggesting additional AR-mediated regulatory interactions between these 
cells (191). 
In addition to vascular cells, we identified a very small population of perivascular cells 
expressing abundant AR in healthy arteries and the number of these AR-positive cells 
increased following vascular injury (191). These unidentified cells may regulate perivascular 
inflammation and the subsequent neointimal lesion development. Recently, Huang et al. 
bred LDLR-/- mice with endothelial cell, smooth muscle cell or macrophage/monocyte-
specific AR knockout to investigate the role of cell-specific AR in atherosclerosis (209). Their 
results suggest that AR in monocytes/macrophages, rather than in endothelial and smooth 
muscle cells, regulates atherogenesis. This study supports the concept that AR expressed in 
non-vascular cells play a critical role in regulation of vascular disease.  
Metabolic effects of androgen  
In addition to the direct effects on vasculature, testosterone plays an important role in 
regulating cardiovascular risk factors such as blood lipid and glucose metabolism in male 
animals. Both endogenous and exogenous testosterone have been reported to reduce LDL 
and VLDL cholesterol as well as atherosclerotic plaques (193,200). The disturbed blood lipid 
homeostasis may be attributed to altered lipid metabolism in the liver where low testosterone 
levels induce hepatic steatosis with dysregulation of lipid assembly and secretion (210,211). 
Furthermore, orchidectomised male mice also demonstrated higher fasting glucose and 
insulin levels (211). By using adipocyte-specific ARKO mice, McInnes et al. demonstrated 
that androgen/AR signalling in adipose tissue is important in maintenance of glucose 
homeostasis (212). The impact of androgens on cardiovascular risk factors will be further 
discussed in section 5.  
DHEA and atherosclerosis  
DHEA (3-15nM) and its sulphated form, DHEAS (3-10µM), are the most abundant steroid 
hormones in the human circulation. DHEA can be converted to androgen and oestrogen at a 
similar rate (213,214). In animal studies, supplementation of DHEA (0.3-0.5% w/w in diet) 
consistently decreases atherosclerosis in both sexes with/without castration (Table 3) 
(195,215-218). Hayashi et al. (217) demonstrated that the anti-atherogenic effects of DHEA 
in ovariectomised female rabbits can be partially (50%) blocked by the aromatase inhibitor 
fadrozole, suggesting a role for conversion of DHEA to oestrogen. Other studies suggest 
that DHEA exerts its effects via ER/AR independent pathways (219,220). Together with the 
fact that DHEA is a very weak agonist for AR/ER and no specific DHEA receptor has been 
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identified, the mechanism through which DHEA protects against cardiovascular disease is 
still elusive. Savineau et al. recently reviewed the cellular and molecular mechanisms of 
DHEA in cardiovascular diseases as well as its metabolic interaction with other endocrine 
hormones (213). 
Effects of androgens on cardiovascular risk factors 
The net effect of androgens on cardiovascular risk is difficult to assess for at least six 
reasons.  
 The risk factors for cardiovascular disease are numerous and ever increasing. 
Testosterone can influence several risk factors simultaneously, some of which at first 
sight appear beneficial, (e.g. lowering lipoprotein(a) (Lp(a)), insulin, fibrinogen, and 
plasminogen activator type 1 (PAI-1)), while others are considered adverse (e.g. 
suppressing HDL-C).  
 Endogenous testosterone appears to have opposite effects on cardiovascular risk 
factors to that of exogenously administered testosterone.  
 The associations between serum concentrations of endogenous testosterone and 
cardiovascular risk factors are confounded by the complex interactions between 
endogenous androgens, body fat distribution, and insulin sensitivity. 
 A causal relationship between some of the aforementioned changes in risk factors 
and atherosclerosis has not been proven. Of particular importance is the example 
where exogenous testosterone -induced suppression of HDL-C may not necessarily 
be accompanied by changes in cardiovascular risk. 
 Testosterone can exert its metabolic effects directly or via its metabolites E2 and 
dihydrotestosterone. The effects of testosterone and E2, in particular, can be either 
be additive (e.g. on Lp(a)) or counter-regulatory (for example on HDL-C).  
 Polymorphisms in the genes encoding the androgen receptor, sex hormone binding 
globulin (SHBG) and 5αreductase regulate genomic effects and bioavailability of 
testosterone and dihydrotestosterone, respectively. Thus, at any given serum 
concentration of testosterone, the metabolic effects at individual target tissue sites 
are pleiotrophic and complex. 
Associations of Endogenous Testosterone with Cardiovascular Risk Factors  
Several population-based studies have found statistically significant correlations between 
plasma levels of testosterone and various risk factors: 
Blood pressure and arterial stiffness 
Several population based studies have shown an inverse relationship between testosterone 
and blood pressure (53,221-228). A similar inverse relationship has also been demonstrated 
between testosterone and arterial stiffness. In a retrospective, cross-sectional study of older 
men, free serum testosterone was negatively correlated with vascular stiffness (229). The 
Baltimore Longitudinal Study of Ageing, in a subpopulation of 206 men, showed serum 
testosterone levels to be an independent negative predictor for developing arterial stiffness 
(230). Studies demonstrating the development of arterial stiffness within three months of 
starting androgen deprivation therapy in patients with prostate cancer further support this 
inverse relationship (231,232). 
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Obesity and body fat distribution 
Population-based studies have shown that endogenous testosterone is consistently and 
inversely associated with BMI. In the EMAS study which included 3200 European men, 
mean total testosterone and free testosterone were significantly lower in overweight (TT –
2.32 nmol/L & FT -17.60 pmol/L) and obese (TT –5.09 nmol/L & FT -53.72 pmol/L) 
compared with the non-obese reference group across all ages (233). The Swedish MrOS 
study, which included an analysis of 2416 men, showed a statistically significant decrease in 
BMI with increasing quartiles of total testosterone (65). The Hypogonadism in Males (HIM) 
study compared 836 hypogonadal men with 1326 eugonadal men. The mean BMI for 
hypogonadal men was found to be 31.5 compared with 28.5 for eugonadal men (234). The 
percentage of body fat evaluated in a study of 57 men aged between 70 and 80 years was 
also found to have negative correlation with testosterone levels (235). 
Several cross-sectional (236,237) and longitudinal studies (238,239) have demonstrated that 
abdominal adiposity is inversely associated with testosterone levels. Studies which have 
used CT or MRI scans to measure abdominal fat have confirmed significant negative 
correlations between testosterone concentrations and visceral fat (240-243).  
Dyslipidaemia and Inflammation 
Observational studies have shown that low endogenous testosterone is associated with high 
total cholesterol, high LDL and low HDL (244).  
The association between levels of endogenous testosterone and the markers of 
inflammation from epidemiological studies shows conflicting results. Some studies (70,245-
249) have shown significant negative associations between testosterone and markers of 
inflammation while others have failed to demonstrate any association (250-253). 
Metabolic syndrome 
It is increasingly appreciated that low serum testosterone in men is associated with 
metabolic syndrome (MetS). Several cross-sectional and longitudinal studies have shown 
negative association of testosterone with MetS.  
Corona et al (2011) demonstrated in a meta-analysis of 20 studies, that patients with MetS 
showed significantly lower testosterone compared to healthy individuals. Lower baseline 
testosterone was demonstrated among patients with incident MetS compared to controls in 
longitudinal studies (254). Brand et al (2011), in another meta-analysis of 52 observational 
studies comprising 22,043 men and 7839 women, showed that endogenous TT and FT 
levels were lower in men with MetS but higher in women with MetS. In both sexes, higher 
SHBG levels were associated with a reduced risk (255). Recently in a further meta-analysis 
of observational studies, Brand et al (2014) showed an inverse relationship between TT, FT 
and SHBG with the MetS (256). The magnitude of associations was largest in non-
overweight men and varied across individual MetS components with stronger associations 
observed with hypertriglyceridaemia, abdominal obesity and hyperglycaemia. The 
associations were weakest for hypertension (256). 
Type 2 Diabetes Mellitus (T2DM) 
A large body of evidence has emerged in the recent years showing a consistent association 
between low testosterone and T2DM. 
In a meta-analysis (257) of prospective studies, there was a difference in testosterone of 
−2.48 nmol /L (95% CI −4.04 to −0.93, P = 0.02) between men with and without T2DM. 
Men with higher testosterone levels (range, 15.6- 21.0 nmol/L) had a 42% lower risk of type 
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2 diabetes (RR, 0.58; 95% CI, 0.39 to 0.87) (258). Longitudinal studies of the cohorts of 
Tromso (259), MRIFT (260), Gothenburg (261), Rancho Bernardo (262), Koppio (263), 
MMAS (264,265) and Cardiovascular Health Study (266) all reported inverse relationships 
between baseline testosterone and future development of T2DM. A further meta-analysis by 
Corona et.al showed a significant inverse association between testosterone and T2DM in 
both cross-sectional and longitudinal studies analyses (267).  
 
The relationship between androgens, body fat distribution, and insulin sensitivity, of which 
the latter two are also involved in the regulation of HDL and triglyceride metabolism, is 
complex (268,269). It is not clear whether androgens regulate adipose tissue and insulin 
sensitivity or whether, vice versa, adipocytes and insulin regulate testosterone levels; 
probably a bi-directional relationship exists. Morbidly obese and insulin resistant men 
frequently have low serum levels of testosterone which increase upon weight loss (270,271). 
E2 levels show the opposite changes to testosterone with obesity and weight loss. It has 
therefore been suggested that obesity may cause hypotestosteronemia by increased 
aromatisation of testosterone to E2 in the adipose tissue but direct evidence for this is 
lacking. Supporting a role of insulin in the determination of testosterone levels in men, 
hyperinsulinemic-euglycemic clamp studies in young healthy men documented that 
increasing insulin resistance was associated with a decrease in Leydig cell testosterone 
secretion (272). In support of the notion that testosterone is the dominant driving factor in the 
bi-directional relationship, however, quantitative CT analysis of hypogonadal men (mean age 
52 years) has shown that they have a greater subcutaneous fat area and a trend towards an 
increased visceral fat area when compared to age-matched eugonadal men (273). 
In summary, low testosterone is associated with all the components of metabolic 
syndrome – central adiposity, hypertension, dyslipidaemia, insulin resistance and 
type 2 diabetes. It is therefore important to measure serum testosterone in these men 
who have symptoms suggestive of testosterone deficiency.  
Role of the Androgen Receptor (AR) 
As androgen action is inversely proportional to the number of CAG repeats in exon 1 of the 
AR gene (274,275), it has been suggested that there may be an association between CAG 
repeat length and cardiovascular disease. Shorter CAG repeat length has been associated 
with both negative predictors of CV risk including lower levels of HDL-cholesterol (276,277) 
and reduced flow-mediated vasodilatation (276) and presumed beneficial changes such as 
lower body fat and plasma insulin in healthy men (278) and reduced body fat in men with 
Type 2 Diabetes (279) or CAD (280) . A shorter CAG repeat length was correlated with more 
severe CAD in men aged 36-86 years of age (280) but not with CAD or MI in middle-aged 
men (277). However the above preliminary results have not been replicated in larger 
population studies. AR CAG repeat numbers did not show any cross-sectional associations 
with serum lipid levels in over 3000 European men (281) nor predicted incident heart 
disease (or changes in HDL-cholesterol, LDL-cholesterol or BMI) in American men followed 
for 15 years (282).  
Effects of Exogenous Testosterone and DHEA on Cardiovascular Risk Factors  
The effects of exogenous androgen on cardiovascular risk factors varies with the dose, 
route, duration and type of treatment, as well as the age, gender and conditions of the 
recipients (for review see (283)). The most consistent findings were decreases in fat mass 
(and increase in lean mass) plasma levels of HDL cholesterol, lipoprotein (a) (Lp(a)) and 
fibrinogen, which are accompanied by much less prominent declines of LDL cholesterol and 
triglycerides . 
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Blood pressure 
Animal studies suggest that androgens may promote retention of sodium and water and 
consequently elevate blood pressure (284). The mechanism for this is thought to be up-
regulation of the renin-angiotensin system in the proximal tubules (284-286). The increased 
risk of developing hypertension with androgens has been confirmed in men who abuse 
anabolic steroids (120,287,288). Randomised, placebo controlled interventional studies with 
testosterone replacement therapy have not shown significant increase in blood pressure. 
However, considering the possibility of elevation of blood pressure by androgens, it 
is important to monitor blood pressure during testosterone replacement therapy. 
Visceral Fat Mass 
Improvement in body composition with reduction in fat mass has been a very consistent 
finding in almost all the testosterone replacement studies. Placebo controlled trials of 
testosterone replacement therapy in ageing men have shown decreases in total fat mass 
ranging from 1- 4.5 kg in studies of 3 – 36 months duration (289). A Malaysian study which 
used intramuscular testosterone undecanoate for 48 months showed significant fat loss 
(290). A recent non randomized Italian study which investigated intramuscular testosterone 
undecanoate in aging men for 5 years showed a reduction in waist circumference by 9.6 +/- 
3.8 cm and weight reduced by 15 +/- 2.8 kg (291). Data on the effects of exogenous 
testosterone specifically on visceral fat are limited. Intra-abdominal visceral fat loss was 
seen (on MRI) in non-obese ageing men treated for 12 months with transdermal 
testosterone (292) and 6 months with intramuscular testosterone (293). Similar results have 
been reported in obese men (294,295). A recent study investigated testosterone 
replacement and withdrawal in severely obese men and showed favourable changes in the 
body composition with testosterone replacement (296). Studies using intramuscular and 
transdermal testosterone in diabetic patients showed significant improvements in body 
composition (297-299). A recent meta-analysis of the management of late onset 
hypogonadism also confirmed that testosterone therapy resulted in significant fat loss (300). 
These data indicate that in men, the dominant action in the bi-directional relationship is that 
testosterone reduces fat mass especially in the abdomen and improves insulin action. In 
agreement, androgens activate the expression of beta adrenergic receptors, adenylate 
cyclase, protein kinase A and hormone sensitive lipase in adipocytes (301). As a result, 
testosterone stimulates lipolysis and thereby reduces fat storage in adipocytes.  
 
Testosterone replacement therapy has favourable effects on visceral adiposity in men 
with obesity having low testosterone. The benefits are possibly greater in men who 
are more obese with lower testosterone. An Australian study which compared TRT 
and lifestyle modification with lifestyle modification alone has shown that TRT offered 
added benefits on visceral fat loss and cardiovascular risk but long term benefits 
versus risk profile needs to be established in further interventional studies. With the 
currently available data, TRT cannot be recommended to be used as a general weight 
loss therapy in obese men who do not have hypogonadism. 
Lipids and Lipoproteins 
HDL-Cholesterol 
In the majority of studies, substitution of testosterone in hypogonadal men and men with 
low/low-normal testosterone levels has decreased HDL-C levels (133,283). In normal young 
men, supraphysiological doses of testosterone or androgen-like anabolic steroids decreased 
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HDL-C by 20% or more. Conversely, surgical castration or medical castration by GnRH 
analogues increased HDL-C (283). In hypogonadal patients or in elderly men, substitution of 
testosterone led to minor or no decrease in HDL-C. Meta-analyses have suggested that 
suppression of HDL-C is directly correlated with the dose of testosterone but inversely 
related to the age and duration of treatment (302-304). Transdermal application of 
testosterone or dihydrotestosterone exerted less effect on HDL-C than oral and 
intramuscular administration. 
Since low HDL-C is an important CAD risk factor and HDL exerts several potentially anti-
atherogenic actions, lowering of HDL-C by testosterone treatment may potentially increase 
cardiovascular risks. However, the epidemiological association of low HDL-C with CAD has 
not been proven to represent a causal relationship. Instead, low HDL-C often coincides with 
other components of the metabolic syndrome, and may therefore merely be a surrogate 
marker for other co-existing pro-atherogenic condition(s). Moreover, in transgenic animal 
models, only increases of HDL-C induced by apoA-I overproduction but not by inhibition of 
HDL catabolism were consistently found to prevent atherosclerosis (305). Therefore, the 
mechanism of HDL modification or turnover rather than levels of HDL-C per se, appear to 
determine the (anti)-atherogenicity of HDL modification (Figure 1).  
Two genes involved in the catabolism of HDL are up-regulated by testosterone, namely 
scavenger receptor B1 (SR-B1) and hepatic lipase (HL). SR-B1 mediates the selective 
uptake of HDL lipids into hepatocytes and steroidogenic cells, including Sertoli and Leydig 
cells, as well as cholesterol efflux from peripheral cells including macrophages. Testosterone 
up-regulates SR-B1 in the human hepatocyte cell line HepG2 and in macrophages and 
thereby stimulates hepatic selective cholesterol uptake and peripheral cholesterol efflux, 
respectively (306). HL hydrolyses phospholipids on the surface of HDL thereby facilitating 
the selective uptake of HDL lipids by SR-B1. The activity of HL in post-heparin plasma is 
increased after administration of exogenous testosterone (307) and slightly decreased by 
suppression of testosterone after GnRH antagonist treatment (308). Increasing both SR-B1 
and HL activities are consistent with the HDL lowering effect of testosterone. Interestingly, in 
transgenic mice, overexpression of SR-BI or HL caused a dramatic fall in HDL-C but 
inhibited rather than enhanced atherosclerosis (305). This again demonstrates the fallacy of 
extrapolating the HDL-C lowering effect of testosterone to increased cardiovascular risk. 
Any effects of exogenous DHEA on cardiovascular risk factors appear to be marginal. In 
men aged 60 – 84 yr, DHEA 100mg daily for 3 months decreased total and HDL-cholesterol 
(309) but this was not confirmed in a larger study (310).  
Lipoprotein (a)  
Results of many case-control studies and most prospective population studies demonstrate 
that lipoprotein(a) (Lp(a)) levels higher than 30 mg/dL (75 nmol/L) are an independent risk 
factor for coronary, cerebrovascular, and peripheral atherosclerotic vessel diseases, 
especially if it coincides with other cardiovascular risk factors (311). Although Lp(a) levels 
are predominantly genetically determined, administration of testosterone to men consistently 
and significantly decreased serum levels of Lp(a) by 25% to 59% (283,312). Conversely 
Lp(a) levels were increased by 40% to 60% in men in whom endogenous testosterone was 
suppressed by treatment with the GnRH analogues (283,313,314). The Lp(a) lowering effect 
of testosterone is independent of E2, which also reduces Lp(a) levels. It is not known how 
testosterone regulates Lp(a). It is also not known whether the decrease in circulating Lp(a) 
induced by testosterone will reduce cardiovascular risk but it illustrates the complex multi-
faceted actions of testosterone on lipid metabolism, the interpretation of which is prone to 
over-simplification. 
LDL and total cholesterol 
Testosterone therapy has been shown to significantly reduce total cholesterol and LDL 
cholesterol in hypogonadal men (315-318). This effect is observed even in eugonadal men 
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(319-321). Physiological testosterone replacement in hypogonadal men with CAD has been 
shown to reduce serum total cholesterol levels despite these patients already being treated 
with statins (322). Meta-analysis of clinical trials has also confirmed that testosterone 
therapy significantly lowers total cholesterol & LDL cholesterol and this effect is also seen in 
men already treated with statins (323). 
 
Lipid Constituents 
Unregulated uptake of oxidatively modified lipoproteins via type A scavenger receptors leads 
to the intracellular accumulation of cholesteryl esters in macrophages and to foam cell 
formation (305). Testosterone increases the oxidation of LDL by placental macrophages in 
vitro (306). In a study which used monocyte-derived- macrophages obtained from healthy 
male and female donors, it was found that DHT dose-dependently stimulates the uptake of 
acetylated LDL by scavenger receptor type A and, hence, the intracellular cholesteryl ester 
accumulation in macrophages. In addition to the higher expression of the androgen receptor 
in male donors, this effect was only seen in macrophages of male but not female donors. 
The stimulatory effect of DHT was blocked by the androgen receptor antagonist 
hydroxyflutamide (324).  
Non-hepatic and non-steroidogenic cells cannot metabolize cholesterol and, therefore, can 
only dispose of excess cholesterol by secretion. Cholesterol efflux from cells is hence central 
to the regulation of the cellular cholesterol homeostasis. Non-specific and passive (i.e. 
aqueous diffusion) as well as specific and active processes (i.e. receptor-mediated) are 
involved. To date, two plasma membrane proteins are known to facilitate cholesterol efflux. 
Interaction of the scavenger receptor B1 with mature lipid-containing HDL is thought to 
facilitate cholesterol efflux by re-organizing the distribution of cholesterol within bilayer 
plasma membrane (Figure 1). The ATP binding cassette transporter A1 mediates 
phospholipid and cholesterol efflux to extracellular lipid-free apolipoproteins by translocating 
these lipids from intracellular compartments to the plasma membrane and/or by forming a 
pore within the plasma membrane, through which the lipids are secreted (145). We have 
found that testosterone up-regulates the expression of the scavenger receptor B1 in human 
monocyte-derived macrophages thereby stimulating HDL-induced cholesterol efflux. No 
effect of testosterone was seen on the expression of the ATP binding cassette transporter 
A1 (231,325,326).  
In a cross-sectional study of 65 men (mean age: 60 + 8 years), serum testosterone had 
strong inverse correlation with anti-oxidised LDL-cholesterol antibody (r=-0.346, p=0.0047). 
The relationship persisted after adjusting for other common CVD risk factors. This would 
suggest either a direct role for testosterone on oxidised LDL-cholesterol metabolism or an 
immune response to oxidised LDL-cholesterol (232). Testosterone replacement in 
hypogonadal men with CAD resulted in a lower HDL-cholesterol and apolipoprotein A1 when 
compared to placebo (230). 
Macrophage Functions 
Circulating monocytes migrate into the vascular wall and differentiate into macrophages. 
They bind to modified lipoproteins which have permeated the vascular endothelium. The 
uptake of modified (e.g. by oxidation) lipoproteins by macrophages leads to the formation of 
large foam cells. These, together with T-lymphocytes, release inflammatory mediators which 
stimulate the proliferation and migration of smooth muscle cells. Human monocyte-derived 
macrophages express the androgen receptor in a gender-specific manner. Macrophages 
from men exhibit a fourfold higher expression of the androgen receptor than macrophages 
from women (327). There is also evidence that testosterone regulates macrophage function 
by non-genomic effects via a G-protein-coupled, agonist-sequestrable plasma membrane 
receptor which initiates calcium- and 1,4,5-triose-phosphate-signaling (328).  
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In summary, testosterone therapy reduces total cholesterol, LDL cholesterol and 
Lp(a) which can be beneficial to reduce cardiovascular risk. It also reduces HDL 
cholesterol. Although low HDL cholesterol is associated with increased 
cardiovascular risk, it cannot be assumed that testosterone induced reduction in HDL 
cholesterol is pro-atherogenic as it may reflect accelerated reverse cholesterol 
transport instead. The effect of testosterone therapy on macrophages could raise the 
possibility of increasing cardiovascular risk by excess production of pro-
inflammatory cytokines. However, the data from clinical studies investigating this 
aspect have been inconclusive. Overall, testosterone therapy does not appear to 
increase pro-atherogenic lipid profile.  
Insulin Resistance and Diabetes 
Young, lean men did not demonstrate any change in insulin sensitivity across a wide range 
of serum testosterone levels in a dose-response study despite a dose-related reduction in fat 
mass (329). Centrally obese middle-aged men receiving testosterone showed an 
improvement in insulin sensitivity (by hyperinsulinaemic / euglycaemic clamp studies) and a 
lowering of serum insulin levels (294). In ageing men hCG administered for 3 months did not 
affect insulin sensitivity (as measured by euglycaemic clamp) (330). It is unclear whether 
changes in serum testosterone regulate insulin sensitivity independent of their effect on fat 
mass (specifically visceral fat). Comparison of data sets is difficult as those middle-aged 
men showing improved insulin sensitivity had higher fat mass and greater waist 
circumference at baseline (163) than the ageing men treated with hCG (330). Whilst 
anabolic steroids (oxandrolone) demonstrate a significant reduction in abdominal fat (295) 
they have been associated with insulin resistance, possibly mediated through a direct 
hepatotoxic mechanism.  
 
Several recent studies have demonstrated varying beneficial effects of testosterone 
replacement therapy on insulin resistance (149,291,297,298,331-341) and type 2 diabetes 
(291,297,298,332,333,342-345), and reduced fat mass (291,304,331,332,342-348). 
 
Cai et al (2014) (349) reviewed five randomised controlled trials including 351 participants 
with a mean follow-up time of 6.5-months, assessing the metabolic effects of testosterone 
replacement therapy on hypogonadal men with type 2 diabetes mellitus. They showed that 
testosterone therapy reduced fasting plasma glucose, fasting insulin, HBA1C and triglyceride 
levels significantly. 
 
A more recent meta-analysis by Grossman et al (2014) (350) of seven randomised 
controlled trials including 833 diabetic men with hypogonadism treated with testosterone for 
periods ranging between 3 to 12 months, demonstrated only modest improvements in insulin 
resistance. There was no improvement in glycaemic control with the mean difference in 
HBA1C of -0.15 (-0.39, 0.10, P 0.25)  
 
In summary, although there are possible favourable effects of testosterone therapy on 
insulin sensitivity, there is no convincing evidence that testosterone treatment 
improves glycaemic control significantly. Therefore one concludes that currently 
testosterone therapy has no role in the management of hyperglycaemia in patients 
with T2DM.  
The Haemostatic System  
In agreement with an important role of thrombus formation in the pathogenesis of acute 
coronary events and stroke, prospective studies have identified various haemostatic 
25 
 
variables as cardiovascular risk factors (351). Among them factor VII, fibrinogen, the 
fibrinolysis inhibitor plasminogen activator inhibitor – 1 (PAI-1) and tissue plasminogen 
activator antigen (tPA) are major factors.  
Effects of testosterone on coagulation cascade and fibrinolytic pathway 
Testosterone has been associated with various pro-thrombotic factors of both extrinsic and 
intrinsic pathways of the coagulation cascade. In a cross-sectional study, low testosterone 
has been associated with higher levels of factor VII and fibrinogen (352). Longitudinal case 
control studies from Norway in elderly men have shown that low testosterone is associated 
with lower plasma levels of the inhibitor protein, tissue factor pathway inhibitor (TFPI), which 
promotes tissue factor induced coagulation (353). In an interventional follow up study, elderly 
hypogonadal men who had testosterone replacement therapy for one year, showed no 
difference in levels of TFPI, activated factor VII or in coagulation time despite normalization 
of testosterone levels (354). Inappropriate timing of laboratory assays with testosterone 
administration, endothelial changes due to aging and differences between short term and 
long term effects of testosterone have been suggested as possible causes for this in a 
further analysis (355).  
The fibrinolytic pathway is initiated by plasmin, stimulated by tissue plasminogen activator 
(tPA) and inhibited by plasminogen activator inhibitor–1 (PAI-1) and plasminogen activator 
inhibitor–2 (PAI–2). Cross sectional studies have shown that lower endogenous testosterone 
levels were associated with higher levels of PAI-I in subjects with coronary artery disease, 
suggesting increased cardiovascular risk from reduced fibrinolysis (24). This negative 
association between endogenous testosterone levels and PAI-1 has also been shown in 
obese patients and those with greater central obesity compared with healthy controls (356). 
In another study similar inverse association between testosterone and PAI-1 has been 
demonstrated in men with newly diagnosed hyperlipidemia (357). Cell culture studies using 
human umbilical vein endothelial cells have demonstrated that physiologic dosing of 
testosterone stimulated tissue plasminogen activator (tPA) and decreased PAI-1 production 
(358).  
 
Administration of supraphysiological dosages of testosterone to 32 healthy men in a trial of 
male contraception, led to a sustained decrease of fibrinogen of 15 to 20% over 52 weeks of 
treatment (359). In this study the doubling of serum testosterone levels initially also led to 
significant decreases of PAI-1, protein S, and protein C as well as to increases of anti-
thrombin and beta-thromboglobulin. Likewise PAI-1 was decreased in men who received the 
anabolic androgen, stanozolol. However, 12-months of a more ‘physiological’ transdermal 
testosterone did not alter PAI-1 or fibrinogen levels in men with chronic stable angina (360). 
Suppression of testosterone in patients with benign prostate hypertrophy by GnRH 
analogues exerted no significant effects on plasma fibrinogen levels (361). In agreement 
with the lowering effects of testosterone on PAI-1, testosterone inhibited the secretion of 
PAI-1 from bovine aortic endothelial cells in vitro.  
Taken together the data indicate that testosterone may lower fibrinogen and PAI-1, 
although the magnitude of effect is likely to vary according to the type and route of 
the administered androgen. However, the evaluation of risk factors associated with 
cardiovascular events in the older men of the TOM trial showed that men who had 
cardiovascular events had significantly higher free testosterone, higher fibrinogen 
levels and significantly lower PAI-1 levels as compared to those who did not have 
cardiovascular events (362). This is suggestive of the possibility that these factors 
could also be contributing to the cardiovascular events in older men.  
Effects of testosterone on platelets 
In the formation of thrombus, platelets play an important role through adhesion to 
endothelium, aggregation and stimulation of coagulation through release of metabolites like 
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thromboxane A2 (TX-A2). These metabolites further promote platelet activity. High dosages 
of androgens were found to decrease cyclooxygenase activity and thereby increase platelet 
aggregability (363). In vitro studies in animal models suggest that testosterone deficiency is 
associated with decreased platelet aggregation and TX-A2 receptor density and that 
testosterone therapy improves both platelet activity and TX-A2 receptor density (357). In a 
randomized blinded placebo controlled study of healthy young men, intramuscular 
testosterone therapy at supraphysiological doses, was shown to increase platelet 
aggregation activity and thromboxane A2 receptor density (358). Surgical or medical 
castration in prostate cancer patients showed reduced platelet TX-A2 receptor density but 
not affinity. This is associated with reduced platelet aggregation but not sensitivity to 
thromboxane mimetic (364). In a study using a human megakaryocytic cell line, 
administration of testosterone in culture resulted in increased gene expression of P2Y12, a 
receptor on the platelet surface which plays an important role in platelet aggregation, 
suggesting another pro-thrombotic mechanism (365). In animal studies with rat aortic 
endothelial cells, testosterone administration in vitro resulted in increased nitric oxide 
production and reduced platelet aggregation (366). Similarly in human umbilical vein 
endothelial cells, testosterone exposure at physiologic concentrations in cell culture resulted 
in increased nitric oxide production and nitric oxide synthase activity, which stopped with 
exposure to supraphysiologic concentrations of testosterone (367).  
 
Testosterone therapy may have pro-thrombotic effect by increasing TX-A2 receptor 
density and promoting P2Y12 receptor expression. It can also have anti-thrombotic 
effect by increasing nitric oxide production. The dominant effect of TRT on platelet 
function needs to be evaluated in further interventional studies. 
 
Testosterone therapy and venous thromboembolism 
A recent series of studies (368-372) have described thromboembolic events in 42 patients 
(38 men and 4 women) who were on androgen replacement therapy. Of the 38 men, 24 
were on transdermal testosterone gel, 13 were on intramuscular injections and 1 patient was 
on nandralone patch. Among 4 women, 2 were on transdermal testosterone patch and the 
remaining 2 were on testosterone – estrogen pellet treatment. Apart from 1 patient who had 
amaurosis fugax and 1 patient who had spinal cord infarction, all others had venous 
thromboembolism. 27 patients had deep venous thrombosis / pulmonary embolism, 12 
patients had osteonecrosis which is thought to be due to thrombosis of the efferent veins of 
the bone leading to increased intracortical pressure and reduced arterial flow and 1 patient 
had central retinal vein thrombosis. The median time for thrombotic events after starting 
testosterone therapy in this series was 5 months. The most recent large retrospective cohort 
and nested case-control analysis which included 102,650 patients treated with TRT and 
102,650 untreated patients with idiopathic VTE, it was found that there was no significant 
increase in the risk of VTE in patients on testosterone therapy (373). In another recent large 
multi-cohort retrospective analysis including 544,155 men on various forms of testosterone 
therapy, the authors did not show an increased risk of VTE (HR 0.92 95% CI 0.76-1.11) 
(123). The possibility of increased risk of VTE in hypogonadal men on TRT was raised 
by few studies. Two large population based studies have reassuringly shown no 
increase in the risk of VTE in men on TRT. Overall, the risk of VTE appears to be 
increased in patients on TRT with underlying genetic hypercoagulable risk.  
 
However, considering significantly increased androgen use in men over 40 years of age and 
the few studies showing increased risk of venous thromboembolism, the United States Food 
and Drug Administration (FDA) is now requiring a change to drug labelling of all testosterone 
products by the manufacturers to provide a more general warning regarding venous blood 
clots and to ensure this risk is described consistently in the labelling of all approved 
testosterone products. 
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(http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProdu
cts/ucm402054.htm) 
Effects of androgens on VASCULAR function 
Blood vessels are specialised tissues lined by a single layered endothelium, with a middle 
muscular layer comprising vascular smooth muscle cells (VSMC), and a fibrous coat – the 
adventitia. The cellular components are held together by a connective tissue framework and 
extracellular matrix.  
Effect of Androgens on Vasomotor Function 
The acute effect of androgen on vascular dilation is well-documented both in clinical and pre-
clinical studies. A high dose of testosterone (>1x10-5M) is able to induce nearly full dilation in 
isolated arteries. Preservation of testosterone-induced vasodilation in arteries lacking 
androgen receptor (AR) suggests that this response is independent of AR activation 
(191,374). Interestingly, similar vasodilation could also be achieved using corticosteroids, 
oestrogen or cholesterol at similar concentrations (>1x10-5M), suggesting this may be a 
common feature of steroids acting directly on the cell membrane (375-377). Given the very 
high concentration required to produce this response, testosterone-induced acute 
vasodilation is very unlikely to have any physiological relevance. 
There is evidence that AR-activation by physiological levels of testosterone modulates 
endothelial function via nitric oxide synthase-dependent mechanisms. Penile erection is an 
archetypal physiological function controlled by nitric oxide (NO) dependent vascular dilation. 
It has been demonstrated that circulating androgen levels correlate with nitric oxide synthase 
expression in the penile vasculature and with erectile function (378,379). Similar regulation 
has also been observed in vasculature of other organs. In cultured male human aortic 
endothelial cells, activation of AR stimulates eNOS phosphorylation and NO production 
within 15 minutes (206). Conversely, normalising circulating testosterone level in 
hypogonadal men reduces the concentrations of asymmetric dimethyl arginine (ADMA; an 
endogenous inhibitor of endothelial NOS) in plasma (380). However, the AR-dependent 
regulation of vasomotor function is more complex. First, acetylcholine-induced endothelial 
NO production and vasodilation in isolated arteries are not affected either in Tfm mice (381) 
or in mice with vascular-specific AR ablation (191). This suggests that the AR-NO signalling 
pathway is not involved in acute regulation of agonist-induced NO production and 
vasodilation. Second, AR-dependent signalling, including NO production, modulates agonist-
induced vasoconstriction. Vasopressin induced a greater vasoconstriction in female mice 
than in males. This gender difference could be abolished by either using AR deficient mice 
or by pharmacologically blocking NOS (381). Ablation of AR in the smooth muscle but not in 
endothelial cells compromises phenylephrine (alpha-adrenergic agonist)-induced 
vasoconstriction (191). As androgen increases alpha-adrenergic receptor expression and 
activity in prostate smooth muscle and cardiac muscle (382,383), the same mechanism may 
also apply to vascular smooth muscle cells. In addition, rats treated with testosterone have 
increased Thromboxane-A2 (TX-A2) receptor density in aortic smooth muscle cells with a 
concomitant increase in response to TX-A2 mimetics (384-386). This modulation of TX-A2 
receptor density in VSMC is mediated by DHT (387) and is more prominent in aortic VSMCs 
from male than from female rats (388). Testosterone has also been shown to directly 
influence vasoconstriction via regulating Neuropeptide Y1 receptor density (389), while 
estradiol has a vasodilatory property by increasing PGI2 production (390) and decreasing 
cytosolic calcium (391). Each of these may be potential mechanisms responsible for gender 
differences in vascular function.  
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In summary, AR may regulate vasomotor function via diverse and opposing mechanisms. 
Indeed, clinical studies also replicate the complex profile of androgen/AR action on vascular 
function brachial artery flow-mediated dilation (FMD) which is commonly used to evaluate 
endothelial function (392). A bolus infusion of 2.3mg testosterone resulted in an increase 
(100-fold) in circulating testosterone concentration within one hour (7.7 versus 770 nM), and 
significantly increased bFMD. However, a vasodilatory effect was not observed with low 
dose testosterone (up to 24 nM) in the same study (393). Given the very high concentration 
required to produce this response, testosterone-induced acute brachial artery vasodilation is 
unlikely to have any physiological relevance. However, circulating testosterone has been 
reported to be negatively associated with FMD in the general population (aged 25 to 85 
years) (394) as well as in prostate cancer patients receiving long-term androgen deprivation 
therapy (395). Surprisingly, androgen replacement therapy of hypogonadal men did not 
improve, but reduced, FMD (396,397). Furthermore, abuse of anabolic steroids among body-
builders impaired vasomotor reactivity without affecting endothelial function (398). These 
findings highlight the complex nature of androgen action on vascular function as well as 
possible detrimental effects of un-physiological testosterone pharmacokinetics associated 
with exogenous testosterone treatment (399). 
 
Effect of Androgens on the Vascular Framework 
 
VSMCs are known to produce proteoglycans (PG) and glycosaminoglycan (GAG), which are 
important constituents of the extra-cellular matrix. Sex steroids have no effects ex vivo on 
GAG (400) or PG (401) synthesis by aortic VSMCs. In aortic VSMCs, testosterone leads to 
preservation of collagen deposition, reduction of elastin/collagen ratio, reduction of fibrillin-1 
deposition and increased Matrix metalloproteinase-3 expression (402). These changes are 
potential mechanisms to explain the increased aortic stiffness observed in males compared 
with females. The gender difference in aortic stiffness might be associated with the male 
preponderance of vascular diseases. However, in a recent study using transgenic mice 
lacking vascular AR, no difference in arterial compliance was found between the transgenic 
and wild type littermates, indicating vascular AR has little impact on arterial structural 
development (191). Mechanism(s) underlying the gender difference in aortic stiffness require 
further investigation.  
OESTROGEN AND CAD IN MEN 
Endogenous Oestrogen 
An increasing body of evidence indicates that important physiological actions of testosterone 
in men are mediated by the oestrogen receptors (ERs) following conversion to oestradiol by 
site-specific aromatases in target tissues (403,404). The existence of two nuclear ER 
subtypes α and β as well as a membrane-bound ER encoded by the same transcript as the 
ERα attest to the potential for many different biological estrogen effects. More recently an 
orphan G-protein coupled receptor 30 (GPR30, now called GPER) was reported to be a new 
type of membrane-bound ER, mediating the non-genomic effects of estradiol (405,406). 
ERs and aromatase are detectable in coronary arteries of monkey and man (407-409). The 
extra-glandular production of oestrogens (with circulating androgens as the immediate 
precursor substrate) may therefore play a role in male cardiovascular physiology and 
pathophysiology. The importance of locally-produced oestrogens from aromatisation of 
testosterone in males for cardiovascular health is highlighted by human and transgenic 
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mouse models of aromatase deficiency and oestrogen resistance. In aromatase-deficient 
men with undetectable circulating oestradiol and oestrone and high testosterone, raised BMI 
with central adiposity, metabolic syndrome, non-alcoholic fatty liver disease and 
dyslipidaemia with elevated total cholesterol, LDL-cholesterol, triglyceride and decreased 
HDL-cholesterol were reported (410,411). These metabolic abnormalities were correctable 
by low dose oestrogen replacement. Insulin resistance, acanthosis nigricans, low HDL-
cholesterol, and impaired glucose tolerance were apparent in a 28 year old male with a null 
mutation in ER gene causing oestrogen resistance (412), with calcium deposition in a 
coronary artery indicating the presence of premature atherosclerosis (413). Flow-mediated 
endothelium-dependent NO-activated vasodilatation in the brachial artery (membrane ER-
mediated) in response to hyperaemia was absent consistent with marked endothelial 
dysfunction (414). 
 
Finkelstein et al. (404) studied the effects of varying doses of transdermal testosterone with 
and without concomitant aromatase inhibitor after suppressing endogenous gonadal steroids 
with goserelin acetate in healthy men. They demonstrated that decreases in lean mass, 
thigh-muscle area, and leg-press strength were attributable to reduced testosterone levels, 
whereas oestrogen deficiency, independent of testosterone, accounted for increases in the 
body fat. The increase in intra-abdominal fat, in particular, with aromatase inhibition may be 
taken to imply excess risks of cardiovascular disease with long-term oestrogen deficiency 
(404). In a further analysis, they also demonstrated that both serum HDL and leptin levels 
showed a marked inverse association with testosterone dose in both cohorts (p<0.001 for 
all). This relationship was not altered by suppressing estrogen production, indicating that 
testosterone alone regulates these measures. In contrast, fasting glucose, HOMA-IR, and 
intramuscular fat increased similarly in all men in the testosterone with aromatase inhibitor 
group, regardless of testosterone dose, and were significantly higher than in the group with 
testosterone without aromatase inhibitor (P<0.05 for all), indicating that estradiol primarily 
regulates these measures. Changes in blood pressure, LDL, and body weight were not 
significantly associated with either testosterone or estradiol levels. (415) 
 
These clinical findings suggest that endogenous oestrogens play an important role in 
maintaining normal carbohydrate and lipid metabolism as well as endothelial function in 
men. They are compatible with data from transgenic knockout models confirming that ERα is 
important in preventing adipocyte hypertrophy, obesity, insulin resistance and 
hypercholesterolaemia (416-418) and maintaining basal NO release from vascular 
endothelium (414) in male animals. ERβ in vascular smooth muscle may also regulate 
vascular reactivity to oestradiol (419). In addition, many in vitro studies have demonstrated 
the direct actions of oestradiol in vasodilatation, inhibition of vascular smooth muscle cell 
proliferation/migration, inhibition of cytokine activation and expression of cell adhesion 
molecules in the vascular inflammatory response, and inhibition of platelet 
aggregation/adhesion (see Section 6 and for review see (420-423)). 
 
Despite indirect evidence supporting possible atheroprotective effects of oestrogen in 
females, the mechanism by which oestrogen protects arteries is controversial. Villablanca et 
al. reported that estradiol prevents atherosclerosis independent of ERα (424) whilst 
stimulation of ERβ attenuates inflammation and atherogenesis (424). In contrast, data from 
Fontaine (425) and Billon-Galés (426) both support that activation of ERα protects against 
atherosclerosis, but disagree about which ERα subunit mediates this effect. In studies using 
male animals, the atheroprotective effect of oestrogen demonstrated apparent gender 
dimorphism; male animals did not benefit from oestrogen supplementation (194,427). 
Indeed, a transgenic animal study demonstrated that the presence of ERα in male arteries 
increases their susceptibility to early atherosclerosis (428). Interestingly, in global AR 
deficient Tfm mice, testosterone-derived estradiol seems to inhibit atherosclerosis via ERα-
dependent mechanisms (192). Further investigation is needed to clarify whether this is due 
to the altered ER expression in these feminized males, or whether the pharmacological dose 
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of supplementation overrides the beneficial effect of oestrogen at a physiological level. 
 
Reports of associations between endogenous oestrogen levels and cardiovascular disease 
in men are conflicting. Epidemiological studies have linked higher endogenous serum 
oestradiol levels with coronary heart disease (in men in the Framingham cohort) (31,429), 
and increased carotid artery intima-media thickness (430) and peripheral arterial disease 
(with men in the MrOS cohort) (431), and yet low oestradiol levels predicted all-cause 
mortality (independent of testosterone) in the MrOS cohort (72) and increased 
cardiovascular disease in the subgroup of older men in the Framingham cohort (59). There 
was no association with cardiovascular morbidity or mortality in the MrFIT (52), Rancho-
Bernardo (53), Honolulu Heart Program (54), BLSA (55), Caerphilly (56), MMAS (41) or 
Tromso (60) cohorts. Interestingly, in a study of men with heart failure, both the highest and 
lowest quartiles of oestradiol predicted increased mortality (432). The relationships between 
oestradiol and the cardiovascular system in men are complex, and despite accounting for 
potential confounders such as lipids, glucose and insulin, the observational nature of these 
studies has inherent limitations in determining the cause and effect nature of the 
relationship. Specifically the effects of oestrogen on SHBG, and the contribution of serum 
testosterone and body fat, particularly visceral fat, are not well understood (433). 
Furthermore, inaccurate measurement of the low levels of oestradiol in men using 
immunoassay methods in the vast majority of the above studies (434) probably contributed 
to these conflicting findings. Recent studies which have used mass spectrometry 
measurements of oestradiol have not shown any significant association of oestradiol with 
cardiovascular disease. In a large population based study of 2143 Australian men, oestradiol 
measured by mass spectrometry was not associated with metabolic syndrome score (435). 
In men of the HIM study cohort, oestradiol measured by mass spectrometry was not 
associated with symptoms of intermittent claudication (436), did not predict the risk of 
myocardial infarction or stroke (64) and also did not predict all- cause mortality (86).   
 
In summary the relationships between oestradiol and the cardiovascular system in 
men are complex, and despite accounting for potential confounders such as lipids, 
glucose and insulin, the observational nature of these studies has inherent limitations 
in determining the cause and effect nature of the relationship. Specifically the effects 
of oestrogen on SHBG, and the contribution of serum testosterone and body fat, 
particularly visceral fat, are not well understood. Furthermore, in the vast majority of 
the above studies, inaccuracies in the measurement by immunoassay of low levels of 
oestradiol in men probably contributed to some of the conflicting findings.  
 
Exogenous Oestrogen 
The therapeutic role of exogenous oestrogens has been studied in cardiovascular disease 
and prostate cancer. Huggins and Hodges first described the use of synthetic oestrogens to 
achieve androgen deprivation in 1941 (437,438) but subsequently the use of oral 
diethylstilboestrol was found to result in an increased number of cardiovascular deaths, 
primarily due to myocardial infarction (439). Although it was hypothesized that the toxicity of 
the oral oestrogens was due to their hepatic metabolism, and subsequent induction of a 
hypercoagulable state, the use of the parenterally administered compound, polyestradiol 
phosphate (PEP), also led to an increase in cardiovascular deaths in men with non-
metastatic disease (440) and non-fatal cardiac events in men with metastatic disease (441). 
High doses of oral conjugated equine oestrogens (2.5mg) resulted in excess deaths when 
administered to men post myocardial infarction in the “Coronary Drug Project” in the 1960’s 
(442). 
31 
 
CONCLUSIONS AND THERAPEUTIC IMPLICATIONS  
 
Current evidence indicates that the sex difference in CAD cannot be explained on the basis 
of ambient testosterone exposure. Androgens can exert both beneficial and deleterious 
actions on a myriad of factors implicated in the pathogenic mechanisms of atherosclerosis 
and CAD. At present, it is not possible to determine the net effect of testosterone on CAD.   
 
The clinical implications of this ongoing uncertainty are; 
1) The concern for the possibility of cardiovascular side effects in androgen 
treatment of endocrine and non-endocrine conditions  
and 
 2) Whether testosterone may be used for the prevention or even treatment of CAD.  
 
Efforts to exploit the therapeutic benefits of testosterone for men in the treatment of 
osteoporosis, sarcopaenia, chronic debilitating disease and age-related hypoandrogenism in 
the ageing male population should take heed of recent concerns regarding the possibility of 
increased cardiovascular event risks (121-123,128).  
 
Some clinicians argue that androgen replacement in the elderly male may have the potential 
to prevent CAD. It is hazardous to extrapolate from cross-sectional observational data 
examining cardiovascular risk factors, or in vitro data studying isolated mechanisms with 
pharmacological doses of androgens, to predict that manipulation of the sex steroid milieu 
will result in clinical benefits in a complex multifactorial condition such as CAD. The lessons 
from estrogen HRT in postmenopausal women are especially salutary. Despite the 
overwhelmingly positive but indirect evidence on risk factors and disease incidence, 
randomised controlled interventional studies recently have not confirmed estrogens to be 
effective in primary or secondary prevention of CAD in women (443-445). Analogously, if 
HRT for ageing men were ever to become an acceptable therapeutic entity, the requirement 
for randomised controlled clinical interventional trials to assess the effects of androgens on 
CAD disease (and other) endpoints is obvious and endorsed by the FDA. In the absence of 
such information on testosterone and DHEA currently, priority must be given to established 
modes of intervention, which have been proven to be effective in prevention or treatment of 
CAD (e.g. weight reduction, smoking cessation, exercise, aspirin, statins/fibrates, anti-
hypertensives, and vasodilators).  
 
For men with established pathological hypogonadism, however, there are no substantive 
data to suggest that physiological testosterone therapy is associated with increased 
cardiovascular risk and their management should not deviate from current recommended 
practice. The issue of initiating or continuing TRT in newly diagnosed or established 
hypogonadal men in association with a major cardiovascular event remains contentious. 
Considering the concerns regarding the possibility of increased cardiovascular risk, expert 
opinion is to delay or stop TRT for 3 to 6 months 
 
 Finally, it is now well recognized that ADT in the treatment of metastatic prostate cancer 
increases cardiovascular risk. These men should have their cardiovascular risk factors 
identified and treated accordingly. 
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Figure 1 Pathways of HDL metabolism and regulation by testosterone and oestradiol  
Mature HDL3 and HDL2 are generated from lipid-free apoA-I or lipid-poor pre β-HDL as the 
precursors. These precursors are produced as nascent HDL by the liver or intestine or are released 
from lipolyzed VLDL and chlyomicrons, or by interconversion of HDL3 and HDL2. ABCA1-mediated 
lipid efflux from cells is important for initial lipidation; LCAT-mediated esterification of cholesterol 
generates spherical particles which continue to grow upon ongoing cholesterol esterification, and 
PLTP-mediated particle fusion and surface remnant transfer. These mature HDL particles also 
continue to accept cellular cholesterol by processes which are facilitated by the scavenger receptor 
BI (SR-BI) and LCAT. Larger HDL2 are converted into smaller HDL3 upon CETP-mediated export of 
cholesteryl esters from HDL onto apoB-containing lipoproteins, SR-B1-mediated selective uptake of 
cholesteryl esters into liver and steroidogenic organs, and HL- and EL-mediated hydrolysis of 
phospholipids. HDL lipids are catabolized either separately from HDL proteins, i.e. by selective 
uptake or via CETP-transfer, or together with HDL proteins, ie. via uptake through as yet unknown 
HDL receptors or apoE receptors. Both the conversion of HDL2 into HDL3 and the PLTP-mediated 
conversion of HDL3 into HDL2 liberate lipid-free or poorly lipidated apoA-I, which is either re-used for 
the formation of mature HDL or is filtrated into the kidney. Grey arrows represent lipid transfer 
processes, black arrows represent protein transfer processes. The hepatic expression and activity of 
both HL and SR-B1 was shown to be up-regulated by testosterone and down-regulated by oestradiol. 
In addition oestradiol up-regulates the hepatic expression and secretion of apoA-I. These actions of 
testosterone and oestradiol are in good agreement with their lowering and increasing effect on HDL 
cholesterol, respectively. In addition both testosterone and oestradiol stimulate SR-BI expression in 
macrophages and thereby cholesterol efflux from these cells onto lipidated HDL. 
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Table 1a Relationships between circulating testosterone levels and coronary artery 
disease in men   
 
Study (reference)a n Hormone 
Endpoint Relationship OR 
     
Mendoza 1983 (11) 52 T MI, angio Negative 
Barth 1983 (12) 20 T CAD, angio Negative 
Hromadova 1985 
(13) 
67 T Coronary angio Negative 
Breier 1985 (14) 139 T CAD, angio Negative 
Aksut 1986 (15) 54 T MI, angina Negative 
Sewdarsen 1986 
(16) 
56 T, free T MI Negative 
Chute 1987 (17) 146 T, free T CAD, angio Negative 
Hämäläinen 1987 
(18) 
57 T, free T CHD, angio Negative 
Lichtenstein 1987 
(19) 
2512 T IHD Negative 
Swartz 1987 (20) 71 T MI Negative 
Sewdarsen 1988 
(21) 
20 T MI, angio Negative 
Sewdarsen 1990 
(22) 
224 T MI Negative 
Rice 1993 (23) 272 T, free T MI Negative 
Phillips et al 1994 
(24) 
55 T, free T CAD, Angio Negative 
Zhao 1998 (25) 201 T CAD Negative 
English 2000 (26) 90 T, free T, bio 
T 
CAD, angio Negative 
Hak 2002 (27) 504 T, free T Aortic calcification Negative 0.4 
(0.1-1.0) 
Luria 1982 (28) 50 T MI Null 
Labropoulos 1982 
(29) 
144 T MI Null 
Zumoff 1982 (30) 117 T MI, CAD Null 
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Phillips 1983 (31) 122 T CHD Null 
Heller 1983 (32) 295 T CHD Null 
Small 1985 (33) 100 T IHD Null 
Franzen 1986 (34) 92 T MI Null 
Baumann 1988 (35) 58 T Atherosclerosis Null 
Slowinska-
Srzednicka 1989 
(36) 
108 T MI, Angio Null 
Cengiz 1991 (37) 55 T MI, angina Null 
Hauner et al 1991 
(38) 
274 T CAD, angio Null 
Mitchell et al 1994 
(39) 
98 T, free T MI Null 
Marquez-Vidal 
1995 (40) 
116 T MI Null 
Feldman et al 1998 
(41) 
1709 T, free T Heart disease Null  0.8 
Kabakci 1999 (42) 337 T, free T CAD, angio Null 
Schuler-Luttmann 
2000 (43) 
189 T, free T 
index 
CAD, angio Null 
  
 
  Turhan 2007 (44) 101 
T, free T 
CAD, angio Negative 
Fallah 2009 (45) 502 T, free T CAD, angio Null 
Gu 2007 (46) 128 T, free T CAD, angio Negative 
He 2007 (47) 414 
T 
CAD, angio Null 
Rosano 2007 (48) 119,  T, bioT CAD, angio Negative 
Dobrzycki et al 
2003 (50)                                                                                                         
96 T, free T CAD, angio Negative 
Hu et al 2011(446) 87 T CAD, angio Negative 
Li et al 2012 (51) 
Park et al 2012 (49) 
803 
291 
T 
T, free T, bio 
T 
CAD, angio 
Coronary calcium 
score, angio 
Negative 
Negative 
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Footnotes: 
a note that all studies were cross-sectional 
T:  total testosterone 
free T: unbound testosterone measured by equilibrium dialysis or analogue assay 
free T index: unbound testosterone derived from total testosterone and SHBG  
bioT:  bioavailable (non-SHBG bound) testosterone   
*adjusted for cardiovascular risk factors 
CAD: coronary artery disease        
CHD: coronary heart disease     
IHD: ischaemic heart disease 
MI: myocardial infarction     
Angio: coronary angiography     
OR: odds ratio (95% confidence intervals) 
Negative relationship indicates lower T levels in patients with CAD compared to controls and 
a null relationship indicates no difference between cases and controls. 
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Table 1b Prospective cohort or nested case-control studies  
 
Study 
(reference) 
n 
(cases, 
controls) 
Type of study, 
duration of 
follow 
Hormone 
Endpoint Relationship 
OR 
Cauley 1987 
(52) 
163, 
163 Nested case-
control 6-8 yr 
T, free T 
MI Null  
Barrett-Connor 
1988 (53) 
1009 Prospective 
cohort 12 yr 
T IHD Null  
Phillips 1988 
(54) 
96, 96 
Nested case-
control 19-20 
yr 
T MI Null 
Contoreggi et al 
1990 (55) 
46, 124 
Nested case-
control 9.5 yr 
T 
CAD Null 
Yarnell 1993 
(56) 
2512 Prospective 
cohort 5 yr 
T CHD Null  
Hautanen et al 
1994 (57) 
62, 97 Nested case-
control 5 yr 
T Cardiac 
endpoints 
Null 
Harman 2001 
(58) 
890 Prospective 
cohort 31 yr 
T, free T 
index 
CAD Null 
Hak 2002 (27) 282 
Prospective 
cohort 6.5 yr 
T, free T 
Aortic 
calcification  
Negative    
Arnlov 2006 
(59) 
2084 
Prospective 
cohort 10 yr 
T CVD Null 
Vikan 2009 (60) 1568 
Prospective 
cohort 10 yr 
T, free T MI Null 
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Akishita et al 
2010 (62) 
171 
Prospective 
cohort 6.5 yr 
T CV events Negative 
Corona et al 
2010 (447)                    
1687 
Prospective 4.3 
yrs 
T MI Negative 
Hyde et al 2011 
(63) 
3637 
Prospective 
cohort 5.1 yr 
T CV events Negative 
Ohlson et al 
2011(65) 
2416 
Prospective 
cohort 5 yr 
T CV events Negative 
Haring et al 
2013 (61) 
254 
Prospective 
cohort 5 yr 
T CV events Null 
Soisson et al 
2013 (66) 
3650 
Prospective 
cohort 4 yr 
T, Bio T CAD J Shaped 
Yeap et al 2014 
(64) 
3690 
Prospective 
cohort 6.6 yr 
T, DHT MI Null 
Shores et al 
2014 (67) 
1032 
Prospective 
cohort 9 yrs 
T, free T, 
DHT 
CVD  Negative 
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Table 1c Relationships between circulating testosterone levels and cardiovascular / 
all-cause mortality in men 
 
Study (ref) 
Cohort / 
Country 
No. 
Age 
(yrs
) 
Follow
-up 
(yrs) 
HR CV 
Mortalit
y 
HR All-
cause 
Mortality 
Summary 
Smith 2005 
(68)  
Caerphilly 2512 52 16.5 
Not 
significa
nt 
Not 
significant 
No 
association 
Araujo 2007 
(69) 
MMAS 1686 55 15.4 
RR: Not 
significa
nt 
RR:Not 
significant 
No 
association 
Vikan 2009 
(60) 
Tromso 1568 60 10.0 
TT – Not 
significa
nt 
FT HR 
1.24 (1.01, 
1.53) 
Low FT is 
associated 
with higher 
risk of all 
cause 
mortality 
Haring 2013 
(61) 
Framingham 
heart study 
254 75.5 10 
Not 
significa
nt 
Not 
significant 
No 
association 
Corona  2010 
(147) 
 
Italy 1687  4.3 
TT 7.1 
(1.8, 
28.6) 
 
Low TT 
associated 
with higher 
CV 
mortality 
Carrero 2011 
(82) 
Sweden 
(ESRD) 
 
260 59 3 
TT 1.9 
(1.0, 3.9) 
 
Low 
testosteron
e is 
associated 
with higher 
risk of CV 
mortality 
Hyde 2012 
(77) 
Australia 3637  5.1 
FT 1.71 
(1.12, 
2.62) 
 
Low 
testosteron
e is 
associated 
with higher 
risk of CV 
mortality 
Khaw  2007 EPIC-Norfolk 2314 67 7.0 
TT 2.29 
(1.60, 
 Low TT is 
associated 
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(71) 3.26) with higher 
CV and all-
cause 
mortality 
Yeap 2014 
(86) 
HIMS 3690  6.7    
Laughlin 
2008 (70) 
Rancho-
Bernardo 
794 74 11.8 
TT 1.38 
(1.02, 
1.85) 
BT 1.36 
(1.04, 
1.79) 
TT 1.44 
BT 1.50 
Low TT 
and BT are 
associated 
with higher 
CV and all-
cause 
mortality 
Carrero 2009 
(83) 
Sweden 
(Hemodialusi
s) 
126 63 3.5 
TT 3.19 
(1.49 , 
6.83) 
TT 2.03 
(1.24, 
3.31) 
Low TT is 
associated 
with higher 
CV and all-
cause 
mortality 
Menke 2010 
(74) 
NHANES III 1114 40 18 
FT 1.53 
(1.05, 
2.23) 
BT 1.63 
(1.12, 
2.37) 
FT 1.43 
(1.09, 
1.87) 
BT 1.52 
(1.15, 
2.02) 
Decrease 
in FT and 
BT is 
associated 
with 
increased 
risk of all-
cause and 
CV 
mortality 
during the 
first 9 
years of 
follow up 
Malkin 2010 
(75) 
UK 
930 
(CAD
) / 
148 
(No 
CAD) 
60.7 
/ 
55.7 
6.9 
BT 2.2 
(1.2, 3.9) 
TT 2.5 
(1.2 to 
5.3) 
BT 2.27 
(1.45, 
3.60) 
TT 1.86 
(1.1 to 3.2) 
Low TT 
and BT are 
associated 
with higher 
CV and all-
cause 
mortality 
Haring 2010 
(73) 
SHIP 1954 58 7.2 
TT 2.56 
(1.15, 
6.52) 
TT 2.24 
(1.41, 
3.57) 
Low TT is 
associated 
with higher 
CV and all-
cause 
mortality 
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Haring 2011 
(84) 
SHIP (CKD 
pts) 
1822 51 9.9 
TT 2.01 
(1.21, 
3.34) 
TT 1.40 
(1.02, 
1.92) 
Low TT is 
associated 
with higher 
CV and all-
cause 
mortality 
Kyriazis 2011 
(85) 
Greece 111 65 3  
TT 2.92 
(1.08, 
7.87) 
TT 2.53 
(1.22, 
5.25) 
Low TT is 
associated 
with higher 
CV and all-
cause 
mortality 
Lerchbaum 
2012 (76) 
LURIC 2069 
54 - 
74 
7.7 
FT 1.77 
(1.23, 
2.55) 
FT 2.11 
(1.60, 
2.79) 
Low FT is 
associated 
with higher 
CV and all-
cause 
mortality 
Shores 2006 
(80) 
Veterans 858 61 4.3  
TT 1.88 
(1.34, 
2.63) 
Low TT is 
associated 
with higher 
all-cause 
mortality 
Lehtonen 
2008 (79) 
Turku 187 71 10  
TT 0.95 
(0.91,1.00) 
Low TT is 
associated 
with higher 
all-cause 
mortality 
Tivesten 
2009 (72) 
MrOS 3014 75 4.5  
TT 1.65 
(1.29, 
2.12) 
Low TT is 
associated 
with higher 
all-cause 
mortality 
Muraleedhar
an 20134 
(81) 
UK 581 59.5 5.8  
TT 2.3(1.3, 
3.9) 
Low TT is 
associated 
with higher 
CV and all-
cause 
mortality 
Yeap 2014 
(86)  
Australia 1920 
70 - 
89 
6.7  
T: quartile 
[Q] 
Q2:Q1=0.8
2 (0.69, 
U shaped 
association 
between 
TT and all-
cause 
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0.98); 
Q3:Q1=0.7
8 (0.65, 
0.94); 
Q4:Q1=0.8
6 
(0.72,1.04) 
mortality 
Pye 2014 
(78) 
EMAS 2599  4.3  
TT 2.3 
(1.2, 4.2) 
Low T is 
associated 
with higher 
risk of all- 
cause 
mortality 
Shores 2014  
(69)(67)  
 
USA 1032 76.5 9  
DHT 
(<25ng/dl) 
HR 1.48 
(1.06, 
2.08) 
DHT (>75 
ng/dl) 
HR 1.42 
(0.99, 
2.04)  
U shaped 
association
. Low and 
high DHT 
associated 
with higher 
all cause 
mortality 
but wide 
confidence 
intervals at 
higher 
levels 
reflect 
uncertainty 
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Table 2 Relationships between circulating DHEA and DHEAS levels and coronary 
artery disease in men  
 
Study (ref) 
n (age, 
yrs) 
Study 
type 
Hormone Endpoint 
Relationship 
OR 
Zumoff 1982  
(30) 
 
38, 79 
(21-85) 
Cross 
DHEA, 
DHEAS 
CAD, angio Positive 
Slowinska-
Srzednicka 
1989  (36) 
108 (26-
40) 
Cross DHEAS MI, angio Negative 
Herrington 
1990 (160) 
101 (<50) Cross 
DHEA, 
DHEAS 
CAD, angio Negative 
Ishihara 1992 
(162) 
69 (15-83) Cross 
DHEA, 
DHEAS 
Aortic calcific, 
pulse wave 
Negative 
Mitchell 1994 
(39) 
98 (<56) Cross DHEAS MI Negative 
Herrington 
1995 (163) 
206 & 61 
(none) 
Cross 
DHEA, 
DHEAS 
Angio, graft 
vasculopathy 
Negative 
Feldman 1998 
(41) 
1709 (40-
70) 
Cross DHEAS Heart disease 
Negative 0.6 
(0.5-0.8) 
Hauner 1991 
(38) 
274 (30-
74) 
Cross DHEAS CAD, angio Null 
Phillips 1994 
(24) 
55 (39-89) Cross DHEAS Angio Null 
Schuler-
Luttmann 2000 
(43) 
189 (<70) Cross al DHEAS CAD, angio Null# 
Hak 2002 (27) 
504 (55-
89) 
Cross DHEAS 
Abdominal 
aortic 
calcification 
Null 0.9 (0.3-
2.2) 
Barrett-Connor 
1986 ((159) 
242 (50-
79) 
Prosp 
cohort 12 
yr 
DHEAS CAD mortality Negative 0.6 
Contoreggi 
1990 (55) 
46, 124 
(41-92) 
Nested 
case-
control 9.5 
DHEAS CAD Null 
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yr 
Lacroix 1992 
(161) 
238, 476 
(48-71) 
Nested 
case-
control 18 
yr 
DHEAS MI, autopsy 
Negative 0.5 
(0.2-1.1) 
Lacroix 1992 
(161) 
238, 476 
(48-71) 
Nested 
case-
control 18 
yr 
DHEAS CAD, MI Null 
Newcomer 
1994 (165) 
157, 169 
(40-84) 
Nested 
Case-
control 28 
mth 
DHEAS MI 
Null 1.0 (0.4-
2.6) 
Barrett-Connor 
1995 (164) 
942 (65.2) 
Prosp 
cohort 19 
yr 
DHEAS CAD deaths Null 
Barrett-Connor 
1995 (164) 
942 (65.2) 
Prosp 
cohort 19 
yr 
DHEAS CAD survivors Negative 0.9 
Berr 1996 
(166) 
266 (66-
>80) 
Prosp 
cohort 4 yr 
DHEAS 
Cardiovascular 
deaths 
Null* 
Jansson 1998 
(168) 
42, 53 
(<70) 
Nested 
Case-
control 
(survivors) 
1yr 
DHEAS 
Reinfarction & 
CAD deaths 
Null 
Tilvis 1999 
(169) 
571(75-
85) 
Prosp 
cohort 5 
yr 
DHEAS CVD deaths Null 
Kiechl 2000 
(170) 
371(40-
79) 
Prosp 
cohort 5 yr 
DHEAS CVD, CIMT 
Null 1.1 (0.9-
1.4) 
Trevedi 2001 
(167) 
963 (65-7) 
Prosp 
cohort 7.4 
yr 
DHEAS CVD mortality 
Null 0.6 (0.3-
1.3) 
Hak 2002 (27) 
287 (55-
89) 
Prosp 
cohort 6.5 
yr 
DHEAS 
Abdominal 
aortic 
calcification 
Null 
Hautanen 1994 62, 97 
Nested 
Case-
DHEAS MI, Cardiac Positive 2.0 
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(57) (48) control 5 
yr 
deaths (1.0-4.9) 
Ohlsson 2010 
(171) 
2644,  
(69-81) 
Prosp 
cohort 4.5 
yrs 
DHEA 
DHEA,S 
CVD deaths Negative 
Tivesten 2014 
(172) 
2416,  
(69-81) 
Prosp 
cohort 5 
yrs 
DHEA 
DHEA,S 
CHD Negative 
Krijthe 2014 
(176) 
1180 
Prosp 
12.3yrs 
DHEA Atrial fibrillation Negative 
Philips 2010 
(173) 
4255, 
Prosp 
cohort 
15yrs 
DHEAS CVD deaths Negative 
Sanders 2010 
(174) 
989, 85.2 
yrs 
Long 
cohort 9 
yrs 
DHEA 
DHEAS 
CVD Negative 
Feldman 
2001(175) 
1167, (40 
– 69) 
Prosp 
cohort 9 
yrs 
DHEA 
DHEAS 
CVD Negative 
Arnlov 2006 
(59) 
1928, 55 
yrs 
Prosp 
cohort, 
10yrs 
DHEAS CVD Null 
 
Cross: cross-sectional study 
Prosp: prospective study 
Long: longitudinal study 
*Negative trend statistically insignificant                 
 # negative only upon univariate analysis, null upon multivariate analysis 
population sample rather than patients   
 fatal cases         
non-fatal cases                              
CAD: coronary artery disease                         
OR: odds ratio (95% confidence intervals)   
CVD: cardiovascular disease                          
CIMT: Carotid intima-media thickness ultrasound   
MI: myocardial infarction                                      
Angio: coronary angiography 
Negative relationship indicates lower DHEA(S) levels in patients with CAD compared to 
controls, positive relationship indicates higher DHEA(S) levels in CAD and a null relationship 
indicates no difference between cases and controls. 
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Table 3  Relationship between androgens and atherosclerosis in animals fed on 
atherogenic cholesterol-enriched diets 
 
Study 
(ref) 
Model n 
Dura
-tion 
Horm-
one 
Circ.T 
Targeted 
vessel 
Measure
-ment 
Effect 
         
Larsen 
1993 
(189) 
Male odx 
rabbits 
36 
17wk
s 
T 
Odx: 1.1-
2.5nM 
Odx +T: 
50-
100nM 
Abdominal 
aorta 
Cholester
ol content 
↓ 
Bruck 
1997 
(194) 
Male odx 
rabbits  
Female 
ovx 
rabbits 
32 
12wk
s 
T 
Odx: 
N.D. 
Odx +T: 
26.5nM 
Aortic 
arch 
Plaque 
area 
↓ in male 
↑ in 
female 
Alexander
-sen 1999 
(195) 
Male odx 
rabbits 
10
0 
30wk
s 
DHEA 
T 
Sham: 
1.28nM 
Odx:  
0.68nM 
Odx 
+DHEA: 
1.89nM 
Odx 
+Oral T: 
2.5nM 
Odx +Inj 
T:  
37.8nM 
Thoracic 
aorta 
Cholester
ol content 
DHEA: 
mod↓ 
Oral T: 
mod↓ 
Inj T: 
sig↓ 
Adams 
1995 
(196) 
Female 
ovx 
monkeys 
64 
24 
mths 
T  
Coronary 
artery 
Plaque 
area 
↑* 
Li 2008 
(199) 
Male odx 
rabbit 
30 
12wk
s 
T 
Sham: 
~20nM 
Odx: 
~2nM 
Odx +T: 
~18nM 
Odx 
+T+flut: 
~18nM 
Aortic 
arch 
Thoracic 
aorta 
Abdominal 
aorta 
Plaque 
area 
Fibrous 
cap 
↓ plaque 
size 
↑ fibrous 
cap 
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Qiu 2010 
(201) 
Male odx 
rabbit 
39 8wks DHT  
Whole 
aorta 
Lipid-
containing 
area 
↓ 
Hatch 
2012 
(200) 
Male 
LDLR−/− 
mice 
5-
11 
/gr
ou
p 
17wk
s 
T  
Aortic 
arch 
Plaque 
area 
↓ 
Elhage 
1997 
(197) 
Male odx 
apoE-/- 
mice§ 
Female 
apoE-/-
ovx mice§ 
70 
70 
8wks 
T & E2 
 
Odx +T: 
5.9nM 
Ovx +T: 
4.5nM 
Aortic 
valve 
Lipid-
containing 
area 
Castrate: 
null 
T and 
E2: ↓ in 
both 
sexes 
Nathan 
2001 
(198) 
Male 
LDLR-/- 
mice 
6-
11 
8wks 
T & E2, 
aromat
ase 
inhibito
r 
 
Aortic 
sinus and 
the 
ascending 
aorta 
Lipid-
containing 
area 
Castrate: 
↑ 
T & E2: 
↓ but 
reversed 
by arom 
inhibitor 
Arad 1989  
(215) 
Male 
rabbits 
15 8wks DHEA 
 
Whole 
aorta 
Lipid-
containing 
area 
↓ 
 
Eich 1993 
(216) 
 
 
Male 
rabbits 
hetero-
topic 
cardiac 
transplant
s 
48 5wks DHEA 
 
Coronary 
artery 
from 
grafted 
heart 
Cross-
sectional 
plaque 
area 
↓ 
 
Hayashi 
2000 
(217) 
 
Female 
ovx 
rabbits 
48 
10wk
s 
DHEA 
 
Descendin
g thoracic 
aorta 
Plaque 
area 
↓ 
Yamakaw
a 2009 
(218) 
Male 
apoE-/- 
24 
12wk
s 
DHEA 
 
Aortic root 
Plaque 
area 
↓ 
Ovx: ovariectomised    
Odx: orchidectomised   
T- testosterone   
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E2: oestradiol     
DHEA: dehydroepiandroterone 
Circ: circulating 
↓: decrease 
↑: increase 
Mod: moderate 
Sig: significant 
Flut: flutamide 
Arom: aromatase 
§ apoE-/- mice: apoE knockout mice  
LDLR-/-mice: LDL-receptor knockout mice   
Cetrorelix: GnRH antagonist  
* T reversed atherosclerosis-related impairment of endothelium-dependent vasodilatation 
response i.e. functional benefit 
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